dorsaVi
Annual Report 2018

Plain-text annual report

dorsaVi Ltd and controlled entities ABN: 15 129 742 409 dorsaVi Ltd (ABN: 15 129 742 409) Annual Report For the Year Ended 30 June 2018 CONTENTS CHAIRMAN’S REVIEW CEO REPORT FINANCIAL REPORT Directors’ Report Auditor’s Independence Declaration Financial Report for the Year Ended – 30 June 2018 Notes to the Financial Statements Directors’ Declaration Independent Auditor’s Report to the Members of dorsaVi Ltd SHAREHOLDER INFORMATION 3 4 8 10 27 28 32 59 60 65 dorsaVi Annual Report 2018 2 CHAIRMAN’S REVIEW dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Dear Shareholders I am pleased to present dorsaVi Ltd’s (dorsaVi) 2018 annual report to our shareholders. Across numerous industries and sectors, we continue to witness the wider adoption of data and analytics. dorsaVi is a fine example of a company that has been able to not only capture this paradigm shift, but capitalise on it too, as we continue to commercialise our market-leading motion analysis technology and bring new and innovative products across the US, UK and Australia. During the year, the Company achieved a number of important milestones, including regulatory clearances, such as the 510(k) clearance of the ViMove2™ by the US FDA; product launches, such as ViMove2™ in the UK and the dorsaVi Professional Suite in the US; and major client deals, including with Stryker, American International Group (AIG) and Curtin University. These milestones are all aligned to our strategic shift as we focus on the US market and aim to grow our annuity revenue streams. The year was also marked by dorsaVi’s operational changes from a strategic perspective. In particular, the Company is focused on driving US market penetration and our CEO, Andrew Ronchi, has relocated to the US since January 2018. This move is in line with our focus on the world’s biggest market for medical devices and workplace health and safety technology. The appetite for wearable solutions in these markets has been strong which the clinical market actively looking for ‘hands-off’ interventions to use with patients to support treatment programs. In the workplace, degenerative manual handling injuries are the leading cause of lost- time injuries in the workplace. With the rate of injury remaining unchanged for many years, organisations are actively looking for innovative interventions which can bring about real change. It is no secret that the US clinical market is a significant opportunity for the Company and is a market advanced in its adoption of new technologies and data when compared to Australia. With this, we have put a strong focus on the US and undertaken the associated operational changes, intending to provide the greatest opportunity for the Company and shareholders alike. Meanwhile, we have also been focused on building our annuity revenue, and we now have two annuity products in-market: myViSafe™ for our workplace safety solution, and dorsaVi Professional Suite (ViMove2™) for the clinical market. While the latter is new to the US market having been released in late June 2018, we are pleased to see growth in our annuity revenues. While this may have a short-term financial impact, the scalability of these products means there is strong potential to add new customers and we view this very favourable for the Company’s long-term prospects and opportunity. As we move into the new financial year, we are optimistic about building on the momentum we’ve secured across our markets. For the US, in particular, we’ve signed large deals with multinational companies such as Stryker and AIG and we aim to convert more global brands currently in our pipeline. This will be an important focus for dorsaVi as we deepen our presence in the US and grow our network there. Equally important will be our desire to raise annuity revenue in the workplace market, as well as strengthen our strategic relationships to bring a rise in sales volume. We are positive we will be able to execute on our strategies and look forward to updating shareholders. On behalf of the board, I would like to thank CEO Andrew Ronchi and his team for their hard work and dedication to dorsaVi and for bringing the Company’s leading technologies to help patients and athletes in their recovery journey and assist companies to improve workplace safety. To our shareholders, we are grateful for your continued support. Greg Tweedly Chairman dorsaVi Annual Report 2018 3 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Introduction CEO REPORT Financial year 2017/18 was a year of continued momentum and strategic change for dorsaVi. As we continued to commercialise our medical grade wearable technology, build out our annuity products and secure larger-scale deals in the US market, we are excited to see how both repeat and new clients have embraced our data-first approach to motion analysis. During the year, we received regulatory clearance for our new Professional Suite product from the FDA and were granted new patents for major markets which solidify our presence, and protect our future, as the market-leading motion analysis technology company. We have been very encouraged to see repeat clients across our portfolio and to have added notable brands to our list of clients, such as Stryker and AIG. dorsaVi also announced a number of important operational changes to deepen our presence in the US. These changes include my relocation to the US, a move which represents our commitment to this market, the appointment of Matt May as General Manager (GM) of dorsaVi and David Erikson as dorsaVi’s new Chief Technology Officer (CTO). Whilst these operational changes have had an impact on the financial performance in the second half of the year, we believe that in the long term these changes will help achieve greater market penetration in the US, which is vital to the business. The appointment of a GM was necessary to facilitate my move to the US. Matt May is an experienced leader having previously worked in a head of operations role at the ASX- listed company Konekt. Matt has been with dorsaVi for four years as Head of Sales and Operations for Australia and we are very pleased to have him step up into this role, allowing myself to focus on the larger scale deals in the US and global customers. “Since being in the US, I have had the opportunity to deepen relationships with existing clients and meet new companies. We are pleased to report that at the time of writing, we have over 25 of the Fortune 100 US companies in our pipeline in active discussion to adopt dorsaVi’s technologies. It is clear that companies in the US have an appetite for the data dorsaVi’s technology produces and we are excited about the potential in this market.” - Andrew Ronchi, CEO, dorsaVi The other major operational change was recruiting a new CTO to bring global technical knowledge and rigour to the dorsaVi product suite. David Erikson brings with him extensive technical and commercial experience in developing hardware, software and data-driven products with multi-national corporates and growth phase companies. Importantly, David has specific experience with medical devices and the regulatory work required to ensure continued FDA compliance. David’s experience has been with world leading companies including Intel, Advanced Micro Devices and Covidien (now Medtronic). We are excited to have David join the dorsaVi team and look forward to having his technical leadership drive product excellence and development efficiency. dorsaVi Annual Report 2018 4 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Our focus for the year ahead is on sales growth in our key markets. We will see sales resource growth in the US and the sales organisation will be focused on selling our core products – Professional Suite (Clinical), ViSafe and myViSafe (workplace). We look forward to sharing our progress with shareholders as our business focuses more on sales execution rather than product development. Financial Summary Compared to last financial year, our full year sales revenue was down 1% this year to $3,433,348. Whilst sales revenue in the first half of the year grew by 12.8% in the second half of the year our revenue was impacted by the operational changes, seasonal factors and the delay of the release of dorsaVi’s Professional Suite in the US. We continue to be pleased with a shift in our revenue streams evidenced by growth in our annuity revenue. Whilst this may impact short term revenue, the scalability of the annuity products means there is strong potential for growth as we add new customers. We believe the growth of our annuity revenue stream bodes well for dorsaVi’s long term prospects. Total expenditure increased by $419,686 (up 5% year on year) mainly due to increases in non-cash expenses such as depreciation and amortisation ($563,604) and the write-off of goodwill ($112,110). The goodwill written off related to workplace compliance services, a service which ceased to be provided during the 2018 year. Cost control continues to be a focus of the business. dorsaVi Clinical Market During the year, dorsaVi made major strides in the clinical market from a regulatory, product and new client perspective. dorsaVi received 510(k) clearance for ViMove2™ (Professional Suite) from the FDA early in the financial year and launched the product in June 2018. The simple and faster-to-use device is patient and clinician-friendly and has a mass market opportunity as we’ve seen in Australia and in the UK. As at 30 June 2018, the Company has sold 128 ViMove2™ systems in these two markets, noting that the formal launch in the latter market only occurred in the second quarter of the year. In addition, dorsaVi also strengthened its intellectual property position with the granting of three new patents - a new knee patent in the US, a body orientation patent in Australia and a running patent in Australia. This brings the number of patent families held by dorsaVi to seven, with 15 patents granted across eight countries. The strengthening of our intellectual property position is critical for the Company not only because it reinforces our leadership and first-to-market position in medical grade wearables, but also because it supports our commercial strategy moving forward. From a product perspective, during the year, Professional Suite was launched in the US, with the first set of pre-orders shipping in June. Professional Suite was designed with a SaaS model in mind, which allows it to be scalable across a large clinical market like the US, where there are approximately 284,000 physical therapists and over 25,000 orthopaedic surgeons. Its SaaS model means users must pay for the hardware upfront and pay an ongoing monthly fee for access to the software licence. A tiered pricing model means the more software products the user buys, the greater the fee collected. Professional Suite is not only the Company’s latest product but it is also an example of how we are growing our annuity revenue. dorsaVi Annual Report 2018 5 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Furthermore, the SaaS model of dorsaVi Professional Suite means it is sold online, and only requires 30 minutes training via a webinar. This is markedly different to the previous generation of the technology which required a face-to-face demonstration and an additional 4-hour training session. This change has freed up resources and allowed our account management staff to focus on new deals and clients. During the year, dorsaVi signed a number of high profile clients in the clinical space. This includes an orthopaedic agreement with Stryker Leibinger GmbH & Co. KG, the German subsidiary of Stryker Corporation, a Fortune 500 company and one of the world’s leading medical technology companies. Earlier in the year, we also signed a ViSafe agreement with Stryker. Another notable deal in the clinical space over the past 12 months is our strategic agreement with Curtin University. We are pleased to see a world class university adopt dorsaVi’s technologies as it validates the dorsaVi technology as a leading and objective biofeedback measurement tool in clinical settings and educates the next generation of physiotherapists on the importance of capturing objective data for patients to achieve optimal clinical outcomes. dorsaVi Workplace Solutions (OHS) As companies across the world are increasingly under pressure to establish preventative practices when it comes to workplace injuries, there is a growing demand for sophisticated and objective technologies that can help improve workplace safety and mitigate injuries. Discussions about workplace safety are no longer the remit of mid-level managers or safety managers but have become important issues at the C-suite and at board-level. This change in attitude has meant Occupational Health and Safety is becoming an increasingly significant opportunity for dorsaVi. During the year, we have been encouraged to see our solutions embraced by organisations of various sizes, whether it be local companies such as Woolworths and Coles, or global corporations such as Amazon and BHP Billiton. We believe this paradigm shift in OHS to adopting data-driven technologies will help fuel dorsaVi’s long term growth as we continue to target large corporations across the US, UK and Australia. Within our ViSafe portfolio, dorsaVi has experienced strong repeat businesses from major brands such as Visy, Tesla, CAT and Heathrow Airport. We also signed new clients ranging from the healthcare sector, such as Johnson & Johnson, to industrial clients such as The Linde Group, a multinational chemical corporation. Worthy of note is our recent agreement with global insurer AIG PC Global Services Inc for a large, two-year multi-country contract. The adoption of ViSafe by a company of AIG’s stature is testament to how our OHS solutions are able to provide new insights and rich data, allowing insurers and major corporates to make data-based decisions using objective data and facts, rather than relying on opinion only. Additionally, the AIG agreement spans the US, UK, Hong Kong and Singapore, with the potential to add more countries, demonstrating the value of engaging with multinational groups. Our self-managed solution, myViSafe™, was designed as an annuity revenue product and we are pleased with the number of clients who are moving to this option when managing their workplace safety. The myViSafe product allows corporations to have a self-service manual handling model where their own risk managers and safety managers perform on-the-spot assessments of workers in their real work environment dorsaVi Annual Report 2018 6 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 and provide real time feedback to the worker. The worker’s data is then uploaded to a central database so that executive management can pinpoint the location of their manual handling risks. As previously noted, annuity revenue is an area of great focus for dorsaVi and will help set up a foundation of ongoing revenue to scale the business. We are pleased to note that as of 30 June 2018, 28 organisations use myViSafe™. dorsaVi Elite Sports The elite sports market continues to be important for the Company as it allows us to align the dorsaVi brand with major names in sport. This market is largely growing via word of mouth referrals. Andrew Ronchi Chief Executive Officer dorsaVi Annual Report 2018 7 FINANCIAL REPORT For The Year Ended 30 June 2018 dorsaVi Annual Report 2018 8 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Financial Report For The Year Ended 30 June 2018 TABLE OF CONTENTS Directors’ Report Auditor’s Independence Declaration Financial Report for the Year Ended – 30 June 2018 Consolidated Statement of Profit or Loss and Other Comprehensive Income Consolidated Statement of Financial Position Consolidated Statement of Changes In Equity Consolidated Statement of Cash Flows Notes to the Financial Statements Directors’ Declaration Independent Auditor’s Report to the Members of dorsaVi Ltd Shareholder Information 10 27 28 28 29 30 31 32 59 60 65 dorsaVi Annual Report 2018 9 Directors’ Report dorsaVi Ltd and controlled entities ABN: 15 129 742 409 The directors present their report together with the financial report of the Group consisting of dorsaVi and the entities it controlled, for the financial year ended 30 June 2018 and auditor’s report thereon. Directors The names of directors in office at any time during or since the end of the year are: Gregory John Tweedly – Non-executive Chairman: Mr. Tweedly was appointed non-executive chairman on 23 November 2017 and served on the Nomination and Remuneration Committee for the whole year. Before being appointed non-executive chairman, Mr Tweedly was a non-executive director and chaired the Audit and Risk Committee. He resigned from the Audit and Risk Committee on 23 November 2017. He was appointed to the Board on 29 October 2013. Ashraf Attia - Non-executive Director: Mr. Attia served on the Audit and Risk Committee for the whole year and was appointed to, and as chair of, the Nomination and Remuneration Committee on 23 November 2017. He was appointed to the Board on 14 July 2008. Michael Panaccio – Non-executive Director: Dr. Panaccio serves on the Audit and Risk Committee and the Nomination and Remuneration Committee. He was appointed to the Board on 16 May 2008. Caroline Elliott – Non-executive Director: Ms Elliott was appointed non-executive director and chair of the Audit and Risk Committee on 24 November 2017. Andrew Ronchi – Chief Executive Officer, Director: Dr. Ronchi was appointed to the Board on 18 February 2008. Herbert James Elliott – Retired 23 November 2017: Before his retirement from the Board on 23 November 2017, Mr Elliott was non-executive Chairman of dorsaVi Ltd and chaired the Nomination and Remuneration Committee. He was originally appointed to the Board on 29 October 2013. The directors have been in office since the start of the year to the date of this report unless otherwise stated. Principal Activities The principal activity of dorsaVi Ltd and its controlled entities during the financial year was distribution of innovative motion analysis technologies. These technologies are commercialised via license, sale or fixed fee consultancy. There has been no significant change in the nature of these activities during the financial year. Results The consolidated loss after income tax attributable to the members of dorsaVi Ltd was $3,727,073 (2017: $3,876,248). dorsaVi Annual Report 2018 10 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Review of Operations dorsaVi Ltd has been listed on the ASX since December 2013. The Group consists of four entities: 1. dorsaVi Ltd, the listed Parent group; 2. dorsaVi Europe Ltd, a wholly owned subsidiary incorporated and domiciled in the UK; 3. dorsaVi USA, Inc., a wholly owned subsidiary incorporated and domiciled in the US; and 4. Australian Workplace Compliance Pty Ltd, a wholly owned subsidiary domiciled in Australia. Revenue for the 2018 financial year was $4,394,271 (2017: $3,897,882) as a result of increases in grant income and foreign exchange gains. Sales revenue was $3,433,348 (2017: $3,466,027). The loss from continuing operations after income tax for the 2018 financial year was $3,727,073 (2017: $3,876,248), a reduction of 4% on the 2017 financial year. dorsaVi Ltd has continued to develop and release new product across all geographic locations. Total expenditure increased by $419,686 (5% year on year) mainly due to increases in non-cash expenses such as depreciation and amortisation ($563,604) and the write-off of goodwill ($112,110). The goodwill written off related to workplace compliance services, a service which ceased to be provided during the 2018 year. OHS Services Revenue for OHS Consultancy, utilising ViSafe technology, was $1,842,411 for the 2018 financial a 4% decline over the 2017 financial year ($1,911,091). Clinical and Sports Product Revenue from the licensing and sale of devices was $1,590,937 for the 2018 financial year up 2% over the 2017 financial year ($1,554,936). With the release of new product during 2018 the directors expect global revenue to grow into the future. Factors impacting and driving this growth include: The effectiveness of the global marketing plan; additional sales generation in the OHS and clinical markets in Australia, Europe and US markets; shortening of the sales lead times; and the rate of uptake of new generation product. Cost of sales decreased in the 2018 financial year to $873,625 (2017: $1,068,139) in line with expectations and as a result of the release of new product. Employee benefits expense for the 2018 financial year was $4,498,316 (2017: $4,302,643), a 5% increase year on year and was inclusive of share-based payments of $447,431 (2017: $371,121). Employee benefits expense represented 50% of the total expenses for the Group for the 2018 financial year (2017: 50%). The material business risks that are likely to have an effect on the financial prospects of the Group include: ▪ ▪ Over time, dorsaVi may be subjected to increased competition if potential competitors develop new technologies or make scientific or systems advances that compare with or compete with dorsaVi’s products. In the medical sector (but not the Elite Sports or OHS sectors), sales and adoption rates of dorsaVi’s system are, in part, likely to be influenced by the availability and level of reimbursement from government and/or insurance payers. Whilst dorsaVi’s products already benefit from reimbursement in some circumstances, there is no guarantee that the use of dorsaVi’s products will receive further reimbursement. ▪ General economic conditions, movements in interest and inflation rates and currency exchange rates may have an adverse effect on the dorsaVi’s activities, as well as on its ability to fund those activities. In particular, much of its future income is expected to come from the US and European markets and therefore dorsaVi’s activities will be affected by currency exchange fluctuations. ▪ dorsaVi is not currently profitable. Proceeds from the initial float and subsequent capital raisings were and are primarily being used to fund, both, the commercial rollout of dorsaVi’s products and continued product development. There is no guarantee that the commercial rollout will result in profitability for the Group. If the commercial roll out is slower or less successful than planned, dorsaVi may need to raise additional capital in the future. dorsaVi Annual Report 2018 11 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Significant Changes in the State of Affairs The following changes in the state of affairs occurred during the period: ▪ On 14 July 2017, dorsaVi Ltd received 510(k) clearance by the US Food and Drug Administration (FDA) for the next generation ViMove2 sensor designed to measure, record and analyse movement and muscle activity of the lower back. ▪ On 14 August 2017, dorsaVi Ltd issued 250,000 fully paid ordinary shares, at $Nil per share, to employees, under the dorsaVi ESOP. The issue of these shares arose on the vesting of 250,000 performance rights previously granted as a result of those employees meeting the performance conditions attached to the rights. ▪ On 6 October 2017, dorsaVi Ltd issued 321,113 fully paid ordinary shares, at $Nil per share, to employees, under the dorsaVi ESOP. The issue of these shares arose on the vesting of 321,113 performance rights previously granted as a result of those employees meeting the performance conditions attached to the rights. On the same day 257,887 performance rights and 78,333 options previously granted, lapsed. ▪ On 18 October 2017, dorsaVi Ltd announced that they had been awarded a Federal Government Advanced Manufacturing Growth Fund grant exceeding $1.1m to assist in the development and implementation of advanced manufacturing activities over a twenty-eight-month period ending March 2020. ▪ On 25 October 2017, dorsaVi Ltd announced that Japara Healthcare (ASX: JHC), one of Australia’s largest aged care providers, will implement dorsaVi’s myViSafe to improve workplace manual handling safety for its staff. ▪ On 23 November 2017, Herb Elliott retired, effective immediately, as Chairman and Director of dorsaVi Ltd. ▪ On 23 November 2017, Greg Tweedly was appointed as Chairman of dorsaVi Ltd at dorsaVi Ltd’s annual general meeting and retired as Chair of the Audit and Risk Committee. ▪ On 24 November 2017, dorsaVi Ltd appointed Caroline Elliott as Non-executive Director and Chair of the Audit and Risk Committee. ▪ On 23 January 2018, dorsaVi Ltd announced that CEO, Andrew Ronchi, had relocated to the US to focus on strategic relationships in the US and Europe and that Matt May had been promoted to General Manager. ▪ On 10 March 2018, dorsaVi Ltd issued 41,250 fully paid ordinary shares, at $Nil per share, to employees, under the dorsaVi ESOP. The issue of these shares arose on the vesting of 41,250 performance rights previously granted as a result of those employees meeting the performance conditions attached to the rights. On the same day 42,084 performance rights previously granted, lapsed. ▪ On 10 April 2018, dorsaVi Ltd announced that the School of Physiotherapy and Exercise Science at Curtin University would conduct a clinical trial assessing low back pain treatment utilising ViMove2 technology to manage patients. ▪ On 22 May 2018, dorsaVi Ltd announced that it had signed a two-year contract with AIG PC Global Services Inc, an affiliate of American International Group (NYSE; AIG) to use dorsaVi’s ViSafe technology to conduct risk assessments for it clients. Initially dorsaVi’s technology would be used in the US, UK, Hong Kong and Singapore. ▪ On 19 June 2018, dorsaVi Ltd announced that a US patent covering the “method and apparatus for monitoring deviation of limb” had been granted. After Balance Date Events With the exception of the following, no matters or circumstances have arisen since the end of the financial year that have significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years. ▪ On 3 July 2018, dorsaVi Ltd announced that it had signed an agreement with CitiPower and Powercor for the provision of dorsaVi’s wearable sensor technology to profile movement risk and improve manual handling safety. ▪ On 18 July 2018, dorsaVi announced that it had signed an evaluation agreement with Stryker Leibinger GmbH & Co to evaluate ViMove2. dorsaVi Annual Report 2018 12 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Likely Developments The following likely developments in the business of the Group are expected to influence its financial results in the near term: ▪ The Group expects to increase, year on year, the annuity revenue proportion of total OHS and Clinical revenue. ▪ The Group expects that, the new product released globally during 2018 and 2019 will support revenue growth. Environmental Regulation The Group’s operations are not subject to any significant environmental Commonwealth or State regulations or laws. Dividend Paid, Recommended and Declared No dividends were paid, declared or recommended since the start of the financial year. Equity Instruments There were no performance rights and options over unissued ordinary shares granted to executives by dorsaVi Ltd during or since the financial year end. There were no performance rights or options over unissued ordinary shares granted to non-executive directors during or since the financial year end. Further details regarding options granted as remuneration are provided in the Remuneration Report below. Shares under Option Unissued ordinary shares of dorsaVi Ltd under option at the date of this report are as follows: Date Options Granted 2 September 2014 24 March 2016 15 May 2017 15 May 2017 15 May 2017 15 May 2017 15 May 2017 Number of Unissued Ordinary Shares under Option 100,000 200,000 550,000 55,000 133,333 133,334 350,000 1,521,667 Issue Price of Shares Expiry Date of the Options $0.40 $0.40 $0.33 $0.33 $0.33 $0.33 $0.33 1 September 2019 24 March 2021 15 May 2022 1 October 2022 1 October 2023 1 October 2024 1 July 2024 No option holder has any right under the options to participate in any other share issue of the Group. Shares Issued on Exercise of Options To the date of this report, there have been no shares issued during or since the end of the year as a result of the exercise of an option over unissued shares. Shares Subject to Performance Rights Unissued ordinary shares of dorsaVi Ltd subject to performance rights at the date of this report are as follows: Date Performance Rights Granted 5 June 2017 5 June 2017 5 June 2017 Number of Unissued Ordinary Shares subject to Performance Rights 547,334 547,332 1,317,000 2,411,666 Issue Price of Shares Vesting Date of Performance Rights - - - 1 October 2018 1 October 2019 1 July 2019 dorsaVi Annual Report 2018 13 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 A performance right holder does not have any right to participate in any other share issue of the Group until the performance rights vest and are converted to ordinary shares. Shares Issued on Vesting of Performance Rights During the year ended 30 June 2018 and to the date of this report, 612,363 shares were issued on the vesting of 612,363 performance rights. During the year ended 30 June 2018 and to the date of this report, 724,971 performance rights were cancelled. There remain 2,411,666 performance rights that do not convert to issued shares unless performance conditions are met, and they vest. Information on Directors and Company Secretary Gregory John Tweedly, B. Com, CPA, GAICD – Non-executive Chairman Greg Tweedly was appointed Chairman of dorsaVi Ltd on 23 November 2017 and served on the Nomination and Remuneration Committee for the whole year. Prior to becoming Chairman, he was a non-executive director and chair of the Audit and Risk Committee. He retired from the Audit and Risk Committee on 23 November 2017. He was appointed to the Board on 29 October 2013. Greg is a Director of Melbourne Health, Deputy Chair Environmental Authority, Chair of the Personal Injury Education Foundation and was a Director and CEO of the Victorian WorkCover Authority (WorkSafe) from 2003 to 2012. Prior to joining WorkSafe, Greg was an executive with the Transport Accident Commission from 1996 to 2002 in various senior roles including Chief Operating Officer. He was formerly a Director of the Emergency Services and Telecommunications Authority, Director of the Institute of Safety Compensation and Recovery Research, a Director of the Personal Injury Education Foundation, a Director and Chair of the Victorian Trauma Foundation, Chair of the Heads of Workers’ Compensation Authorities of Australia and New Zealand and Member of SafeWork Australia and its predecessor organisation. No other directorships of listed companies were held during the three years to 30 June 2018. Ashraf Attia, BSc (Eng)(Hons), MSc (Biomed. Eng), Dip (Mktg), FAICD – Non-executive Director Ash Attia chairs the Nomination and Remuneration Committee and serves on the Audit and Risk Committee. He was appointed to the Board on 14 July 2008. Ash has had extensive senior management experience in multinational operations for over 25 years within the medical devices, biotechnology and diagnostics industries. He is currently Vice President Asia Pacific and Middle East for TransMedics Inc. Prior to that, he held the position of Managing Director, Asia Pacific for St Jude Medical/Thoratec, a Group with global revenues of over 5.5 billion, which manufactures and sells cardiac assist devices for use by patients with heart failure. Ash has also consulted to several organisations in the areas of business development, strategic marketing, sales and marketing management, and distribution strategies. No other directorships of listed companies were held during the three years to 30 June 2018. Michael Panaccio, BSc (Hons), MBA, PhD, FAICD – Non-executive Director Michael Panaccio serves on the Audit and Risk Committee and the Nomination and Remuneration Committee. He was appointed to the Board on 16 May 2008. Michael is one of the founders of Starfish Ventures Pty Ltd, an Australian based venture capital manager. He was formerly an Investment Manager with JAFCO Investment (Asia Pacific). Prior to joining JAFCO, Michael was Head of the Department of Molecular Biology at the Victorian Institute of Animal Sciences. Michael has previously been a director of numerous technology businesses in Australia and the US including ImpediMed Ltd, SIRTeX Medical Ltd, Protagonist Therapeutic Inc and Energy Response Pty Ltd. With the exception of ImpediMed Ltd, no other Directorships of listed companies were held during the three years to 30 June 2018. Michael is also a director of Starfish Ventures Pty Ltd, Armaron Bio Ltd, Ofidium Pty Ltd, Mimetica Pty Ltd, MetaCDN Pty Ltd and Cylite Pty Ltd. dorsaVi Annual Report 2018 14 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Caroline Elliott, B. Ec, CA, GAICD – Non-executive Director Caroline Elliott was appointed to the Board on 24 November 2017 and is chair of the Audit and Risk Committee. Caroline is currently a Director of the National Film and Sound Archive of Australia, St John’s Ambulance Australia (Vic) and Wiltrust Nominees Pty Ltd. She has previously held non-executive director roles at Cell Therapies, Peter MacCallum Cancer Centre and the Public Transport Ombudsman Limited. She is currently the Chief Operating Officer at retail fashion business Kookai and was previously the CFO and Company Secretary at Optal Limited. No other directorships of listed companies were held during the three years to 30 June 2018. Andrew Ronchi, B. App. Sci. (Physio), PhD (RMIT Eng), GAICD – Chief Executive Officer, Director Andrew Ronchi was appointed to the Board on 18 February 2008. Before co-founding dorsaVi, Andrew was a practising physiotherapist both at an AFL club and in private practice. He is a founding partner in two physiotherapy centres, the largest of these employing 28 staff (including 13 physiotherapists). Prior to the formation of dorsaVi, Andrew undertook a PhD in Computer and Systems Engineering, investigating the reliability and validity of transducers for measuring lumbar spine movement. As CEO of dorsaVi Ltd, Andrew is responsible for all aspects of the Group’s operations. No other directorships of listed companies were held during the three years to 30 June 2018. Brendan Case, MComLaw (Melb), BEc, CPA, Grad Dip App Fin, Dip FP, FCIS Brendan Case has served as dorsaVi Ltd’s secretary since October 2013 and has more than 20 years of company secretarial, corporate governance and finance experience. He is a former Associate Company Secretary of National Australia Bank Limited (NAB), former secretary of NAB’s Audit and Risk Committees and has held senior management roles in risk management and regulatory affairs. Directors’ Meetings The number of meetings of the board of directors and of each board committee held during the financial year and the numbers of meetings attended by each director were: Mr G Tweedly Mr A Attia Ms C Elliott (App. 24 Nov. 2017) Dr M Panaccio Mr H Elliott (Ret. 23 Nov. 2017) Dr A Ronchi Mr G Tweedly Mr A Attia Dr M Panaccio Mr H Elliott (Ret 23 Nov. 2017) Board of Directors Eligible to Attend 10 10 6 10 4 10 Attended 10 10 5 10 4 10 Audit and Risk Committee Attended Eligible to Attend 1 2 1 2 - - 1 2 1 2 - - Nomination and Remuneration Committee Eligible to Attend 6 4 6 2 Attended 6 4 6 2 Directors’ Interest in Shares, Performance Rights or Options as at 30 June 2018 Names of Holders Michael Panaccio Andrew James Ronchi Ashraf Attia Gregory John Tweedly Ordinary Shares of dorsaVi Ltd 72,421,255 8,406,546 211,139 86,347 The directors have no interests in performance rights or options over shares in dorsaVi Ltd as at the date of this report with the exception of Andrew Ronchi who has an interest in 750,000 performance rights which, dorsaVi Annual Report 2018 15 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 subject to the satisfaction of performance conditions, can vest into shares progressively over the next two financial years. Indemnification and Insurance of Directors and Officers The Group has insured its Directors, Secretary and executive officers for the financial year ended 30 June 2018. Under the Group’s Directors and Officers Liability Insurance Policy, the Group cannot release to any third party or otherwise publish details of the nature of the liabilities insured by the policy or the amount of the premium. The Group also indemnifies every person who is or has been an officer of the Group against any liability (other than for legal costs) incurred by that person as an officer of the Group where the Group requested the officer to accept appointment as Director. To the extent permitted by law and subject to the restrictions in section 199A and 199B of the Corporations Act 2001, the Group indemnifies every person who is or has been an officer of the Group against reasonable legal costs incurred in defending an action for a liability incurred by that person as an officer of the Group. ASIC Instrument on Rounding of Amounts In accordance with ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2016/191, the amounts in the directors’ report and in the financial statements have been rounded to the nearest dollar. Indemnification and Insurance of Auditors No indemnities have been given or insurance premiums paid during or since the end of the financial year for any auditors of the Group. Proceedings on behalf of the Group No person has applied for leave of Court to bring proceedings on behalf of the Group. Auditor’s Independence Declaration A copy of the auditor’s independence declaration as required under section 307C of the Corporations Act 2001 in relation to the audit for the financial year is provided with this report. Non-audit Services Non-audit services are approved by resolution of the audit committee and approval is provided in writing to the board of directors. Non-audit services were provided by the auditors of entities in the consolidated group during the year, namely Pitcher Partners Melbourne, network firms of Pitcher Partners, and other non- related audit firms, as detailed below. The directors are satisfied that the provision of the non-audit services during the year by the auditor is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001 for the following reasons: ▪ All non-audit services were subject to the corporate governance procedures adopted by dorsaVi Ltd and have been reviewed and approved by the Audit Committee to ensure they do not impact on the integrity and objectivity of the auditor; and ▪ The non-audit services provided do not undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants, as they did not involve reviewing or auditing the auditor’s own work, acting in a management or decision making capacity for dorsaVi Ltd or any of its related entities, acting as an advocate for dorsaVi Ltd or any of its related entities, or jointly sharing risks and rewards in relation to the operations or activities of dorsaVi Ltd or any of its related entities. Amounts Paid and Payable to Pitcher Partners Melbourne for Non-audit Services: Taxation and Other Compliance Services Total Remuneration for Non-audit Services 2018 $ 2017 $ 23,450 23,450 26,831 26,831 dorsaVi Annual Report 2018 16 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Remuneration Report (Audited) The Directors present the Group’s 2018 Remuneration Report, which details the remuneration information for dorsaVi Ltd’s, Non-Executive Directors, Executive Directors and other Key Management Personnel (KMP). A. Details of the Key Management Personnel Period of Responsibility Position Directors Greg Tweedly Herb Elliott Caroline Elliott Ashraf Attia Michael Panaccio Full Year Retired 23 November 2017 Appointed 24 November 2017 Full Year Full Year Chairman (from 23 November 2017), Non- Executive Director Chairman, Non-Executive Director Independent, Non-Executive Director Independent, Non-Executive Director Non-Executive Director Executive Director Andrew Ronchi Full Year Chief Executive Officer/Director Executives Matthew May Damian Connellan Megan Connell Meagan Blackburn David Erikson Muhammad Umer Zoë Whyatt Mark Heaysman Full Year Full Year Full Year Full Year Appointed 16 April 2018 Resigned 30 April 2018 Full Year Until 11 April 2018 General Manager Chief Financial Officer Chief Marketing Officer Chief Innovation Officer Chief Technology Officer Software Architect Chief Operating Officer, Europe Chief Operating Officer, USA B. Remuneration Policies Nomination and Remuneration Committee The Nomination and Remuneration Committee of the Board of Directors is responsible for making recommendations to the Board on the remuneration arrangements for each Non-Executive Director (NED), Executive Director/Chief Executive Officer (CEO) and each Executive reporting to the CEO. The current members of the Nomination and Remuneration Committee are: Ashraf Attia, Michael Panaccio and Greg Tweedly. The Nomination and Remuneration Committee assess the appropriateness of the nature and amount of remuneration of executives on a periodic basis by reference to relevant employment market conditions with the overall objective of ensuring maximum stakeholder benefit from the retention of high quality, high performing directors and executive team. In determining the level and composition of executive remuneration, the Nomination and Remuneration Committee may also engage external consultants to provide independent advice. The primary responsibility of the Nomination and Remuneration Committee is to review and recommend to the Board: ▪ Executive remuneration and incentive policies and practices; ▪ The Executive Director's total remuneration having regard to remuneration and incentive policies; ▪ The design and total proposed payments from any executive incentive plan and reviewing the performance hurdles for any equity-based plan; ▪ The remuneration and related policies of Non-Executive Directors for serving on the board and any committee (both individually and in total); and ▪ Any other responsibilities as determined by the Nomination and Remuneration Committee or the Board from time to time. Remuneration Strategy The remuneration strategy of dorsaVi Ltd is designed to attract, motivate and retain Employees, Executives and Non-Executive Directors in Australia, the United States and Europe by identifying and rewarding high performers and recognising the contribution of each employee to the continued growth and success of the Group. dorsaVi Annual Report 2018 17 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 To this end, the key objectives of the Group’s reward framework are to: ▪ Align remuneration with the Group’s business strategy; ▪ Offer an attractive mix of remuneration benchmarked against the applicable market’s region and country practices; ▪ Provide strong linkage between individual and Group performance and rewards; ▪ Offer remuneration based on internal equity with other employees and individual skill matching the role requirements with their experience and responsibilities; ▪ Align the interests of executives and shareholders and share the success of the Group with the employees; and ▪ Support the corporate mission statement, values and policies through the approach to recruiting, organizing and managing people. Remuneration Structure In accordance with best practice corporate governance, the structure of the non-executive directors and executive remuneration is separate and distinct. Non-Executive Director Remuneration Structure The ASX Listing Rules specify that an entity must not increase the total aggregate amount of remuneration of Non-Executive Directors without the approval of holders of its ordinary securities. The Board, and since its inception the Nomination and Remuneration Committee, considers the level of remuneration required to attract and retain Directors with the necessary skills and experience for the Group’s Board. This remuneration is reviewed with regard to market practice and Directors’ duties and accountability. The constitution provides that the Non-Executive Directors are entitled to remuneration for their services as determined by the Board up to an aggregate limit of $500,000 (which may be increased with Shareholder approval). The Group has obtained advice about remuneration levels for Directors of listed companies and, based on that advice, set the following annual non-executive Directors’ fees: ▪ Chairman: $75,092 plus superannuation; ▪ Other Directors: $50,000 plus superannuation; and ▪ Further fees for acting as chairman of a committee: $5,000 plus superannuation per committee. The Group determines the maximum amount for remuneration, including thresholds for share-based remuneration for Executives, by resolution. The remuneration received by the Non-Executive Directors for the year ended 30 June 2018 is detailed in Table 1 of this section of the report. Non-executive directors receive fees and do not receive incentive payments or share based payments. Executive Remuneration Structure The Group provides a remuneration package that incorporates both cash-based remuneration and share- based remuneration. The contracts for service between the Group and executives are on a continuing basis the terms of which are not expected to change in the immediate future. Share-based remuneration is conditional upon continuing employment thereby aligning director and shareholder interests. Remuneration consists of the following key elements: ▪ Fixed remuneration (base salary and superannuation); and ▪ Variable remuneration – short term incentives (STI) in the form of an annual incentive plan and long- term equity incentive (LTI). STI and LTI are currently only provided to KMP by way of share-based payments and include no cash component. Fixed Remuneration Objective Fixed remuneration is reviewed annually by the Board / Nomination and Remuneration Committee. The process consists of a review of the Group and individual performance, relevant comparative remuneration from external and internal sources and where appropriate, external advice on policies and practices. dorsaVi Annual Report 2018 18 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Structure Executives are given the opportunity to receive their fixed remuneration in a variety of forms including cash and allowances (such as motor vehicle allowance). It is intended that the manner of payment chosen will be optimal for the recipient without creating undue cost for the Group. Variable Remuneration – Short-Term Incentive (STI) Objective The key objective of the STI program is to link the achievement of the Group’s operational targets with the remuneration received by the executives charged with meeting those targets. Structure Any STI granted depend on the extent to which specific targets set at the beginning of the financial year or on appointment are met. The Key Milestones or Key Performance Indicators (KPI’s) cover individual, team and organisational financial measures of performance. Typically included are measures such as: Achieving sales/revenue targets and/or growth, and meeting Group compliance requirements. These measures were chosen as they represent the key drivers for the short-term success of dorsaVi. The Group has predetermined benchmarks that must be met in order to trigger STI under the STI scheme. Either on an annual or financial year basis, after consideration of performance against the Key Milestones or KPIs, the Nomination and Remuneration Committee, in line with their responsibilities determine the amount, if any, of the STI to be awarded to each Executive. This process usually occurs within one month after the trigger date. Typically, STI awards are made under the Employee Share Ownership Plan (ESOP) and are delivered in the form of share options or performance rights. Each option entitles the holder to one fully paid ordinary share of dorsaVi Ltd at an exercise price to be determined in accordance with the ESOP or by determination by the Nomination and Remuneration Committee. Each performance right vested entitles the holder to one fully paid ordinary share of dorsaVi Ltd at $Nil price. The annual STI available for executives across the Group are subject to the approval of the Nomination and Remuneration Committee. Variable Remuneration – Long-Term Incentive (LTI) Objective The objectives of providing long term incentives are: To motivate and retain key dorsaVi employees; to attract quality employees; to create commonality of purpose between dorsaVi and its employees; to add wealth for all shareholders of the Group through the motivation of dorsaVi’s employees; and by allowing dorsaVi’s employees to share the rewards of the success of dorsaVi through the acquisition of, or entitlements to, shares and options. Structure The Board offers LTIs to reward the performance of employees, which is in alignment with shareholders’ interests and the long-term benefit of the Group. LTI awards are made under the Employee Share Ownership Plan (ESOP) and are delivered in the form of share options, performance rights or loan for shares. Each option entitles the holder to one fully paid ordinary share of dorsaVi Ltd at an exercise price to be determined in accordance with the ESOP or by determination by the Nomination and Remuneration Committee. Each performance right vested entitles the holder to one fully paid ordinary share of dorsaVi Ltd at $Nil price. Where an LTI participant ceases employment prior to vesting in their award, the options and unvested performance rights are forfeited unless the Nomination and Remuneration Committee applies its discretion to allow vesting at or post cessation of employment in appropriate circumstances. Options and performance rights have been granted, under the ESOP plan. See Table 6. dorsaVi Annual Report 2018 19 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Employment Agreements The Group has entered into Employment Agreements with all executives, including the CEO. The Group may terminate the Executive’s Employment Agreements by providing at least one month’s written notice or providing payment in lieu of the notice period (based on the fixed component of the executive’s remuneration). The Group may terminate the contract at any time without notice if serious misconduct has occurred. The notice periods for key management personnel are as follows: Notice Period Name 6 months Andrew Ronchi Matthew May 3 months Damian Connellan 3 months Megan Connell Meagan Blackburn 8 weeks’ notice until 3 years of continuous employment. One additional week for 8 weeks David Erikson Zoë Whyatt each completed year of continuous employment up to a maximum of 12 weeks’ notice. 3 months 12 weeks CEO Remuneration In January 2018 Andrew Ronchi relocated to the USA. Before his relocation his fixed remuneration was $250,000 per annum plus superannuation giving a total of $273,750 inclusive of superannuation. Subsequent to his relocation his fixed remuneration is US$360,000, including medical benefits insurance, plus director’s fees of A$25,000 per annum. In addition, Andrew Ronchi has, as approved at a meeting of shareholders, been granted 900,000 performance rights. The vesting of these performance rights is subject to performance conditions over three years but will not fully vest before 29 November 2019. During 2018; 75,000 of these performance rights vested into shares and 75,000 lapsed. As at 30 June 2018; 750,000 of these performance rights remained outstanding. Upon termination of Andrew Ronchi’s employment contract, he will be subject to a restraint of trade for a maximum of 12 months. C. Details of Key Management Personnel Remuneration (a) Non-Executive Directors’ Remuneration: Table 1 2018 Salary fees Pension Plan Short-Term Post-employment TOTAL Non-Executive Directors H Elliott (ii) C Elliott (iii) A Attia M Panaccio (i) G Tweedly $ 30,975 32,083 54,781 54,120 66,888 $ 2,943 3,048 5,204 - 6,354 $ 33,918 35,131 59,985 54,120 73,242 (i) Michael Panaccio provides his services via Starfish Technology Fund II, LP. (ii) Retired 23 November 2017 (iii) Appointed 24 November 2017 238,847 17,549 256,396 Total performance related Share based payments as % of total % - - - - - - % - - - - - - 2017 Salary fees Pension Plan Short-Term Post-employment TOTAL Non-Executive Directors H Elliott A Attia M Panaccio (i) G Tweedly $ 74,341 54,450 54,120 49,912 $ 7,062 5,173 - 9,710 $ 81,403 59,623 54,120 59,622 (i) Michael Panaccio provides his services via Starfish Technology Fund II, LP. 232,823 21,945 254,768 Total performance related Share based payments as % of total % - - - - - % - - - - - dorsaVi Annual Report 2018 20 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (b) Executives’ Remuneration: Table 2 Short-Term Post- employment Share-based payments TOTAL Total performance related Share based payments as % of total 2018 Salary, fees Other (i) Pension Plan Equity (ii) $ $ $ $ $ % % Executive Director A Ronchi (iii) 343,302 13,861 22,524 103,255 482,942 Executives M Blackburn D Connellan M Connell D Erikson (iv) M Heaysman (iii) (v) M May M Umer (vi) Z Whyatt (iii) 205,000 109,200 140,000 38,528 278,039 235,000 177,380 138,841 - - - - 16,501 - - 17,143 19,475 - 13,299 3,660 - 19,762 11,875 4,165 60,984 - 40,553 - 43,257 66,710 - 54,943 285,459 109,200 193,852 42,188 337,797 321,472 189,255 215,092 1,665,290 47,505 94,760 369,702 2,177,257 - - - - - - - - - - 21.4 21.4 - 20.9 - 12.8 20.8 - 25.5 17.0 (i) Other benefits include the payment of certain health and disability related insurance premiums in the US and UK. (ii) Share based payments comprise mixture of the grant of options, performance rights, and, loan shares backed by an interest free, no-recourse loan. For accounting purposes, all these equity instruments are valued the same as options. (iii) Foreign currency amounts are converted into AUD at the average exchange rates applicable throughout the year. (iv) Commenced 16 April 2018. (v) Ceased to be a KMP, 11 April 2018. (vi) Resigned, 30 April 2018. Short-Term Post- employment Share-based payments TOTAL Total performance related Share based payments as % of total 2017 Salary, fees Other (i) Pension Plan Equity (ii) $ $ $ $ $ % % Executive Director A Ronchi 249,999 - 19,616 97,402 367,017 Executives M Blackburn D Connellan M Connell M Heaysman (iii) M May M Umer Z Whyatt (iii) 205,000 109,289 119,013 281,039 205,000 150,000 134,431 - - - 68,062 - - 16,659 19,475 - 11,306 9,738 19,475 14,250 4,033 8,560 - 4,410 33,629 39,252 3,378 104,254 233,035 109,289 134,729 392,468 263,727 167,628 259,377 1,453,771 84,721 97,893 290,885 1,927,270 - - - - - - - - - 26.5 3.7 - 3.3 8.6 14.9 2.0 40.2 15.1 (i) Other benefits include the payment of a relocation allowance and health and disability related insurance premiums in the US and UK. (ii) Share based payments comprise mixture of the grant of options, performance rights, and, loan shares backed by an interest free, no-recourse loan. For accounting purposes, all these equity instruments are valued the same as options. (iii) Foreign currency amounts are converted into AUD at the average exchange rates applicable throughout the year. D. Relationship between Remuneration and Group Performance (a) Remuneration Not Dependent on Satisfaction of Performance Condition The non-executive remuneration policy is not directly related to Group performance. The Board considers a remuneration policy based on short-term returns may not be beneficial to the long-term creation of wealth by the Group for shareholders. dorsaVi Annual Report 2018 21 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (b) Remuneration Dependent on Satisfaction of Performance Condition A portion of the Executive Remuneration is based on attainment of performance conditions. Performance- based remuneration includes short-term cash bonus and long-term incentive plan. Performance-based remuneration granted to key management personnel has regard to Group performance over a twelve month to 2-year period. The following table summarises the performance conditions for KMP with performance-linked equity instruments: Table 3. KMP Andrew Ronchi Matthew May Damian Connellan Megan Connell Meagan Blackburn David Erikson Zoe Whyatt Conditions for vesting of Options and Performance Rights Key Milestones as determined by and at the discretion of the Board Key Milestones as determined by and at the discretion of the Board Key Milestones as determined by and at the discretion of the Board Key Milestones as determined by and at the discretion of the Board Key Milestones as determined by and at the discretion of the Board Key Milestones as determined by and at the discretion of the Board Key Milestones as determined by and at the discretion of the Board These vesting conditions were selected to promote the creation of shareholder wealth during the period. The following Table sets out the Terms and Conditions of each Grant of the Performance-Linked Bonus affecting Compensation in Current and Future Years: Table 4 As at the date of this report the following performance linked bonuses are payable for key management personnel. Awarded/Available Forfeited Total Potential Performance Link Bonus $ 103,255 60,984 40,553 43,257 66,710 54,943 2018 % 70% 72% 76% 52% 61% 68% % 30% 28% 24% 48% 39% 32% A Ronchi M Blackburn M Connell M Heaysman M May Z Whyatt (i) All performance bonuses are in the form of performance rights that convert to shares on their vesting date, 1 October 2018 or 1 January 2019, or options, and have been valued at the market share price on date of grant. (c) Consequences of Group’s Performance on Shareholder Wealth The following Table summarises Group Performance and Key Performance Indicators: Table 5 Company Performance Revenue % increase in revenue Loss before tax % (increase)/decrease in loss before tax Change in share price Dividend paid to shareholders Return of capital Total remuneration of KMP Total performance-based remuneration 2018 4,394,271 13% 2014 767,418 42% (4,640,744) (4,717,447) (5,915,567) (8,684,709) (4,121,606) 2015 1,850,416 141% 2017 3,897,882 20% 2016 3,238,138 75% 2% (59%) - - 2,433,653 20% 7% - - 2,182,038 32% 4% - - 2,450,850 (111%) (41%) - - 2,442,136 (90%) 10% - - 1,213,960 369,702 290,885 98,264 140,295 79,512 dorsaVi Annual Report 2018 22 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 E. Key Management Personnel’s Share-Based Compensation (a) Details of Compensation Equity Table 6 2018 Grant Date (i) Number Granted Value per unit at grant date $ Vested during the year Year in which equity may vest Executives A Ronchi: 29-Nov-16 29-Nov-16 29-Nov-16 29-Nov-16 Z Whyatt: 15-May-17 15-May-17 15-May-17 15-May-17 15-May-17 M Heaysman: (ii) 3-Jul-14 17-Aug-15 5-Jun-17 5-Jun-17 5-Jun-17 M Connell: 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 M Blackburn: 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 M May: 5-Nov-14 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 M Umer: (iii) 25-Feb-15 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 150,000 150,000 150,000 450,000 500,000 133,333 133,333 133,334 350,000 250,000 500,000 83,334 83,334 333,332 50,000 50,000 50,000 150,000 100,000 100,000 100,000 150,000 20,000 100,000 125,000 125,000 125,000 200,000 30,000 25,000 25,000 25,000 75,000 0.45 0.45 0.45 0.45 0.33 0.33 0.33 0.33 0.33 0.04 0.17 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.27 0.31 0.31 0.31 0.31 0.31 0.23 0.31 0.31 0.31 0.31 75,000 - - - - 55,000 - - - - - 31,250 - - 33,750 - - - 67,000 - - - - 100,000 52,500 - - - - 16,063 - - - 2018 2019 2020 2020 2017 2018 2019 2020 2020 2017 2020 2018 2019 2020 2018 2019 2020 2020 2018 2019 2020 2020 2019 2017 2018 2019 2020 2020 2020 2018 2019 2020 2020 Terms and conditions for each grant Lapsed/re- moved during the year Exercise Price Expiry Date First Exercise Date Last Exercise Date $ 75,000 - - - - - - - 1-Oct-17 1-Oct-18 1-Oct-19 29-Nov-19 N/A 1-Oct-18 1-Oct-19 29-Nov-19 N/A 1-Oct-18 1-Oct-19 29-Nov-19 Vest % 50% - - - 100% - 0.33 15-May-22 15-May-17 41% - - - - - 37% - - 68% - - - 67% - - - 100% 100% 42% - - - 100% 64% - - - 78,333 - - - 250,000 500,000 52,084 83,334 333,332 16,250 - - - 33,000 - - - - - 72,500 - - - 30,000 8,937 25,000 25,000 75,000 0.33 0.33 0.33 0.33 0.46 0.26 - - - - - - - - - - - 0.40 - - - - - 0.36 - - - - 1-Oct-22 1-Oct-23 1-Oct-24 1-Jul-24 3-Jul-19 17-Aug-20 1-Jan-18 1-Jan-19 1-Jan-20 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 5-Nov-19 1-Jul-17 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 25-Feb-20 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 N/A N/A N/A N/A N/A N/A 1-Oct-18 1-Oct-19 1-Jul-19 N/A 1-Oct-18 1-Oct-19 1-Jul-19 N/A N/A N/A 1-Oct-18 1-Oct-19 1-Jul-19 N/A N/A N/A N/A N/A 15-May- 22 1-Oct-22 1-Oct-23 1-Oct-24 1-Jul-24 N/A N/A N/A N/A N/A N/A 1-Oct-18 1-Oct-19 1-Jul-19 N/A 1-Oct-18 1-Oct-19 1-Jul-19 N/A N/A N/A 1-Oct-18 1-Oct-19 1-Jul-19 N/A N/A N/A N/A N/A 5,025,000 430,563 1,657,770 The options and performance rights granted during 2017 are subject to performance and retention conditions. (i) (ii) M Heaysman ceased to be a member of the KMP, 11 April 2018. (iii) M Umer resigned, 30 April 2018. As at 30 June 2018, no options have been exercised and, accordingly, no shares have been issued as a result of options previously vested. During the year ended 30 June 2018, 375,563 shares have been issued as a result of performance rights vesting and 382,771 Performance rights lapsed. dorsaVi Annual Report 2018 23 2017 Terms and conditions for each grant Grant Date (i) Number Granted Value per unit at grant date Vested during the year Year in which equity may vest Vest Lapsed during the year Exercise Price Expiry Date First Exercise Date Last Exercise Date dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Executives A Ronchi: 29-Nov-16 29-Nov-16 29-Nov-16 29-Nov-16 Z Whyatt: 30-Sep-15 30-Sep-15 30-Sep-15 15-May-17 15-May-17 15-May-17 15-May-17 15-May-17 M Heaysman: 3-Jul-14 17-Aug-15 5-Jun-17 5-Jun-17 5-Jun-17 M Connell: 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 M Blackburn: 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 M May: 5-Nov-14 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 M Umer: 25-Feb-15 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 150,000 150,000 150,000 450,000 250,000 250,000 250,000 500,000 133,333 133,333 133,334 350,000 250,000 500,000 83,334 83,334 333,332 50,000 50,000 50,000 150,000 100,000 100,000 100,000 150,000 20,000 100,000 125,000 125,000 125,000 200,000 30,000 25,000 25,000 25,000 75,000 $ 0.45 0.45 0.45 0.45 0.28 0.28 0.28 0.33 0.33 0.33 0.33 0.33 0.04 0.17 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.31 0.27 0.31 0.31 0.31 0.31 0.31 0.23 0.31 0.31 0.31 0.31 - - - - - - - 500,000 - - - - - - - - - - - - - - - - - - - - - - - - - - - - % - - - - - - - 100% - - - - - - - - - - - - - - - - - 100% - - - - - 100% - - - - - - - - 250,000 250,000 250,000 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2018 2019 2020 2020 2016 2017 2018 2017 2018 2019 2020 2020 2017 2020 2018 2019 2020 2018 2019 2020 2020 2018 2019 2020 2020 2019 2017 2018 2019 2020 2020 2020 2018 2019 2020 2020 $ - - - - 0.28 0.28 0.28 0.33 0.33 0.33 0.33 0.33 0.46 0.26 - - - - - - - - - - - 0.40 - - - - - 0.36 - - - - 5,775,000 500,000 750,000 (i) The options and performance rights granted during the current year are subject to performance and retention conditions. F. Key Management Personnel’s Equity Holdings (a) Number of Equity Holdings held by Key Management Personnel 1-Oct-17 1-Oct-18 1-Oct-19 29-Nov-19 - - - 15-May-22 1-Oct-22 1-Oct-23 1-Oct-24 1-Jul-24 3-Jul-19 17-Aug-20 1-Jan-18 1-Jan-19 1-Jan-20 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 5-Nov-19 1-Jul-17 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 25-Feb-20 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 1-Oct-17 1-Oct-18 1-Oct-19 29-Nov-19 - - - 15-May-17 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 1-Oct-17 1-Oct-18 1-Oct-19 29-Nov-19 - - - 15-May-22 1-Oct-22 1-Oct-23 1-Oct-24 1-Jul-24 N/A N/A 1-Jan-18 1-Jan-19 1-Jan-20 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 N/A 1-Jul-17 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 N/A 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 N/A N/A 1-Jan-18 1-Jan-19 1-Jan-20 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 N/A 1-Jul-17 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 N/A 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 As at 30 June 2018, key management personnel held options, under the Group’s Employee Share Ownership Plan 2013, to purchase 1,171,667 ordinary shares of the Group. As at 30 June 2018, 555,000 of these options had vested and were convertible to shares. As at 30 June 2018, key management personnel held 2,216,666 performance rights, under the Group’s Employee Share Ownership Plan 2013, which, on vesting, convert to 2,216,666 ordinary shares of the Group. As at 30 June 2018, none of these performance rights had vested and converted to shares. dorsaVi Annual Report 2018 24 (b) Number of Shares held by Key Management Personnel (Consolidated) The relevant interest of each key management personnel in the share capital of the Group as notified the ASX as at 30 June 2018 is as follows: dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Table 7 2018 Non-Executive Directors H Elliott (i) A Attia C Elliott M Panaccio M Panaccio (relevant interest) G Tweedly Executive Director A Ronchi Executives M Connell D Connellan M Blackburn D Erikson Z Whyatt M Umer (i) M Heaysman (ii) M May Balance 1/07/17 Received as Remuneration Net change Other Balance 30/06/18 100,097 211,139 - 71,421,255 1,000,000 86,347 - - - - - - 8,331,546 75,000 - - 271,579 - 63,496 795,442 1,168,972 20,000 33,750 - 67,000 - - 16,063 31,250 152,500 (100,097) - - - - - - - - - - - (811,505) (1,200,222) - 211,139 - 71,421,255 1,000,000 86,347 8,406,546 33,750 - 338,579 - 63,496 - - - 172,500 83,469,873 375,563 (2,111,824) 81,733,612 (i) Resigned during the year. (ii) Ceased to be a KMP during the year. G. Loans to Key Management Personnel (a) Aggregate of Loans Made There were no loans made to key management personnel during the 2018 financial year (2017: $Nil). There were no outstanding loans to key management personnel as at 30 June 2018 (30 June 2017: $Nil). H. Other Transactions with Key Management Personnel (a) Transactions with Key Management Personnel of the Entity or its Parent and their Personally Related Entities During the nine-month period ended 11 April 2018, dorsaVi Ltd paid $70,864 (2017: $104,038) to Safety Assess Pty Ltd a related Company of Dane Heaysman. These amounts are on normal commercial terms and were paid to these parties in their capacity as ViSafe Assessors on various ViSafe projects throughout the financial year. Dane Heaysman and the company are related to dorsaVi through Dane’s relationship to his father, Mark Heaysman. Mark Heaysman ceased to be a KMP on 11 April 2018. (b) Transactions with Other Related Parties Starfish Ventures Pty Ltd is a related party as it is connected with a director of dorsaVi Ltd. During the year ended 30 June 2018, Starfish Ventures Pty Ltd charged rent to dorsaVi Ltd. Total value of these rental charges was $109,346 (2017: $121,970). The rent was charged to dorsaVi on normal terms and conditions. The balance outstanding at balance date was $15,047 (2017: $14,916) included in Trade Payables at Note 14. dorsaVi Annual Report 2018 25 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 During the year ended 30 June 2018, dorsaVi Ltd paid $54,140 (2017: $54,120) to Starfish Technology Fund II, LP on behalf of Michael Panaccio for director’s fees. I. Use of Remuneration Consultants During the year the Board did not engage remuneration consultants. J. Voting and Comments made at the Group’s 2017 Annual General Meeting (AGM) At the Group’s most recent AGM, resolution to adopt the prior year remuneration report was put to the vote and at least 75% of ‘yes’ votes were cast for adoption of that report. No comments were made on the remuneration report that was considered at the AGM. -----------------------------------End of the Remuneration Report------------------------------------------ Signed in accordance with a resolution of the directors Greg Tweedly Director and Chairman Andrew Ronchi Director and CEO Melbourne Date: 19 September 2018 Melbourne Date: 19 September 2018 dorsaVi Annual Report 2018 26 AUDITOR’S INDEPENDENCE DECLARATION   To the Directors of dorsaVi Ltd.  In relation to the independent audit for the year ended 30 June 2018, to the best of my knowledge and belief there  have been:  (i) (ii) No contraventions of the auditor independence requirements of the Corporations Act 2001; and No contraventions of APES 110 Code of Ethics for Professional Accountants. This declaration is in respect of dorsaVi Ltd. and the entities it controlled during the year.  F V RUSSO  Partner  19 September 2019  PITCHER PARTNERS  Melbourne  An independent Victorian Partnership ABN 27 975 255 196   Level 13, 664 Collins Street, Docklands VIC 3008  Liability limited by a scheme approved under Professional Standards Legislation Pitcher Partners is an association of independent firms  Melbourne | Sydney | Perth | Adelaide | Brisbane | Newcastle  An independent member of Baker Tilly International  27Financial Report for the Year Ended – 30 June 2018 CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2018 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Revenue and other income Sales revenue Other income Less: Expenses Cost of sales Advertising expenses Conference expenses Consultancy expenses Depreciation and amortisation expenses Device development expenditure Employee benefits expenses Write-off of goodwill Occupancy expenses Professional fees Regulatory expenses Software expenses Travel expenses Other expenses 4 4 5 5 5 5 5 Notes 2018 $ 2017 $ 3,466,027 431,855 3,897,882 (1,068,139) (239,990) (72,596) (332,815) (174,677) (181,033) 3,433,348 960,923 4,394,271 (873,625) (244,742) (88,292) (362,075) (738,281) (26,654) (4,498,316) (4,302,643) (112,110) (356,250) (543,182) (90,474) (219,786) (387,902) (493,326) - (283,078) (446,470) (86,800) (170,261) (447,460) (809,367) (9,035,015) (8,615,329) Loss before income tax benefit Income tax benefit (4,640,744) (4,717,447) 6 913,671 841,199 Loss from continuing operations (3,727,073) (3,876,248) Other comprehensive income Items that may be reclassified subsequently to profit and loss: Exchange differences on translation of foreign subsidiaries net of tax Other comprehensive income for the year Loss for the year (443,571) (443,571) (4,170,644) 308,995 308,995 (3,567,253) Loss per share for loss from continuing operations attributable to equity holders of the parent entity: Basic loss per share Diluted loss per share 20 20 (2.22 cents) (2.22 cents) (2.45 cents) (2.45 cents) The above statement should be ready in conjunction with the accompanying notes. dorsaVi Annual Report 2018 28 CONSOLIDATED STATEMENT OF FINANCIAL POSITION FOR THE YEAR ENDED 30 JUNE 2018 Notes 2018 $ dorsaVi Ltd and controlled entities ABN: 15 129 742 409 2017 $ 8,609,602 2,410,615 317,157 146,125 3,966,857 2,189,079 324,934 235,995 6,716,865 11,483,499 3,884,253 324,331 4,208,584 2,607,199 381,094 2,988,293 10,925,449 14,471,792 1,084,644 381,782 1,466,426 41,858 41,858 1,508,284 9,417,165 930,084 385,696 1,315,780 30,340 30,340 1,346,120 13,125,672 38,455,224 38,440,518 731,407 758,286 (29,769,466) (26,073,132) 9,417,165 13,125,672 Current assets Cash and cash equivalents Receivables Inventories Other assets Total current assets Non-current assets Intangible assets Plant and equipment Total non-current assets Total assets Current liabilities Payables Provisions Total current liabilities Non-current liabilities Provisions Total non-current liabilities Total liabilities Net assets Equity Share capital Reserves Accumulated losses Total equity 8 9 10 11 12 13 14 15 15 16 17 17 The above statement should be ready in conjunction with the accompanying notes. dorsaVi Annual Report 2018 29 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2018 Consolidated Entity Share capital Reserves $ $ Accumulated losses $ Total Equity $ Balance as at 1 July 2016 Loss for the year Exchange differences on translation of foreign operations, net of tax Total comprehensive income for the year Transactions with owners in their capacity as owners: Issue of shares Cost of raising capital Redemption of Employee share ownership plan Employee share ownership plan Options lapsed 30,709,796 - 93,496 - (22,212,210) (3,876,248) 8,591,082 (3,876,248) - - 308,995 - 308,995 308,995 (3,876,248) (3,567,253) 7,999,972 (309,411) 40,161 - - 7,730,722 - - - 371,121 (15,326) 355,795 - - 7,999,972 (309,411) - - 15,326 15,326 40,161 371,121 - 8,101,843 Balance as at 30 June 2017 38,440,518 758,286 (26,073,132) 13,125,672 Balance as at 1 July 2017 Loss for the year Exchange differences on translation of foreign operations, net of tax Total comprehensive income for the year Transactions with owners in their capacity as owners: Redemption of Employee share ownership plan Employee share ownership plan Options lapsed 38,440,518 - 758,286 - (26,073,132) (3,727,073) 13,125,672 (3,727,073) - - (443,571) - (443,571) (443,571) (3,727,073) (4,170,644) 14,706 - - 14,706 - 447,431 (30,739) 416,692 - - 30,739 30,739 14,706 447,431 - 462,137 Balance as at 30 June 2018 38,455,224 731,407 (29,769,466) 9,417,165 The above statement should be ready in conjunction with the accompanying notes. dorsaVi Annual Report 2018 30 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2018 Notes 2018 $ 2017 $ Cash flow from operating activities Receipts from customers Payments to suppliers and employees Grants received Interest received Income tax refunded Net cash used in operating activities Cash flow from investing activities Payment for plant and equipment Payment for intangibles Net cash used in investing activities Cash flow from financing activities Proceeds from share issue Cost of raising capital Proceeds from employee share ownership plan Net cash provided by financing activities Reconciliation of cash Cash at beginning of the financial year Net (decrease) / increase in cash held Cash at end of the year 4,389,596 (8,316,837) 347,051 112,182 870,640 (2,597,368) 3,475,183 (7,947,085) 258,370 148,588 678,220 (3,386,724) 18 (b) (49,980) (2,010,103) (2,060,083) (133,492) (1,630,089) (1,763,581) - - 14,706 14,706 8,609,602 (4,642,745) 3,966,857 18 (a) 7,999,972 (309,411) 40,161 7,730,722 6,029,185 2,580,417 8,609,602 The above statement should be ready in conjunction with the accompanying notes. dorsaVi Annual Report 2018 31 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Notes to the Financial Statements TABLE OF CONTENTS NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES NOTE 2: SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS NOTE 3: FINANCIAL RISK MANAGEMENT NOTE 4: REVENUE AND OTHER INCOME NOTE 5: LOSS FROM CONTINUING OPERATIONS NOTE 6: INCOME TAX NOTE 7: DIVIDENDS NOTE 8: CASH AND CASH EQUIVALENTS NOTE 9: RECEIVABLES NOTE 10: INVENTORIES NOTE 11: OTHER ASSETS NOTE 12: INTANGIBLE ASSETS NOTE 13: PLANT AND EQUIPMENT NOTE 14: PAYABLES NOTE 15: PROVISIONS NOTE 16: SHARE CAPITAL NOTE 17: RESERVES AND ACCUMULATED LOSSES NOTE 18: CASH FLOW INFORMATION NOTE 19: COMMITMENTS AND CONTINGENCIES NOTE 20: LOSS PER SHARE NOTE 21: SHARE BASED PAYMENTS NOTE 22: DIRECTORS' AND EXECUTIVE COMPENSATION NOTE 23: SUBSIDIARIES AND RELATED PARTY DISCLOSURES NOTE 24: AUDITOR'S REMUNERATION NOTE 25: PARENT ENTITY INFORMATION NOTE 26: SEGMENT INFORMATION NOTE 27: SUBSEQUENT EVENTS 33 41 42 44 45 45 45 46 46 46 46 46 47 48 49 49 50 51 51 52 52 55 55 56 56 57 58 dorsaVi Annual Report 2018 32 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2018 NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES The following is a summary of significant accounting policies adopted by the Group in the preparation and presentation of the financial report. The accounting policies have been consistently applied, unless otherwise stated. (a) Basis of Preparation of the Financial Report This financial report is a general-purpose financial report that has been prepared in accordance with Australian Accounting Standards, Interpretations and other applicable authoritative pronouncements of the Australian Accounting Standards Board. The financial report covers dorsaVi Ltd and controlled entities as a Group. dorsaVi Ltd is a company limited by shares, incorporated and domiciled in Australia at: Level 1, 120 Jolimont Road, East Melbourne East, Victoria, 3002. dorsaVi Ltd is a for-profit entity for the purpose of preparing the financial statements. The financial report was authorised for issue by the directors on the date of the director’s report. Compliance with IFRS The consolidated financial statements of dorsaVi Ltd also comply with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB). Historical Cost Convention The financial report has been prepared under the historical cost convention, as modified by revaluations to fair value for certain classes of assets and liabilities as described in the accounting policies. Significant Accounting Estimates and Judgements The preparation of the financial report requires the use of certain estimates and judgements in applying the entity’s accounting policies. Those estimates and judgements significant to the financial report are disclosed in Note 2. (b) Going Concern The Group incurred a loss from ordinary activities after income tax of $3,727,073 during the year ended 30 June 2018 (2017: $3,876,248) and had a net decrease in cash held of $4,642,745 (2017: Net increase in cash held $2,580,417). As at 30 June 2018, the Group’s current assets exceed current liabilities by $5,250,439 (2017: $10,167,719). The 2018 financial year has been a year of strategic change for the Group. The Group has continued its focus into driving penetration into the US clinical market and focused on building annuity revenue streams. Whilst, these strategic changes have seen a short-term financial impact on the Group through cash burn and low growth in revenue, in the longer term, the size of the US clinical market and scalability of annuity products, should provide the greatest opportunity for the Group and its shareholders. In determining the basis for preparation of the financial report, the Directors have reviewed the financial performance, future operating plans (including cashflow forecasts), financial position and existing cash resources available to the Group. The Directors are confident that the Group will be able to continue as a going concern for at least 12 months from the date of authorisation of the financial report, which contemplates continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business. Should the need arise in the medium to long-term, the Company will seek to raise additional working capital through capital raises. As a result of the above, the Directors have concluded that the going concern basis is appropriate. Whilst the Directors are confident that the above initiatives will generate sufficient funds to enable the Group to continue as a going concern for a period of at least 12 months from the date of signing the financial report, should these initiatives be unsuccessful, there exists a material uncertainty that may cast significant doubt on the ability of the Group to continue as a going concern and therefore, whether it will be able to realise its assets and extinguish its liabilities in the normal course of business, and at the amounts stated in the financial report. dorsaVi Annual Report 2018 33 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (c) Principles of Consolidation The consolidated financial statements are those of the Group, comprising the financial statements of the parent entity and of all entities, which the parent entity controls. The Group controls an entity when it is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are prepared for the same reporting period as the parent entity, using consistent accounting policies. Adjustments are made to bring into line any dissimilar accounting policies, which may exist. All inter-company balances and transactions, including any unrealised profits or losses have been eliminated on consolidation. Subsidiaries are consolidated from the date on which control is established and are de- recognised from the date that control ceases. (d) Revenue Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer and the costs incurred or to be incurred in respect of the transaction can be measured reliably. Risks and rewards of ownership are considered to have passed to the buyer at the time of delivery of the goods to the customer. Revenue from the provision of services to a customer is recognised upon performance of the service. Accrued income arising from recognised revenue is transferred to trade receivables when project milestones are achieved, and tax invoices are raised. Certain customers may be invoiced in advance of the provision of services and this unearned income is recognised as a liability until the service is performed. Revenue from fixed price contracts is recognised by reference to the stage of completion. The stage of completion is determined using inputs from dorsaVi’s project management methodology, including effort expended and effort to complete. Revenue from grants is recognised in accordance with the recognition and measurement requirements of AASB 120 “Accounting for Government Grants and Disclosure of Government Assistance”. Revenue from grants does not include refundable research and development tax offsets. These are accounted for within Income Tax Expense. Interest revenue is recognised when it becomes receivable on a proportional basis taking into account the interest rates applicable to the financial assets. Device rental income is recognised on a straight-line basis over the term of the rental term. All revenue is stated net of the amount of goods and services tax (GST). (e) Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less held at call with financial institutions, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the statement of financial position. (f) Inventories Inventories are measured at the lower of cost and net realisable value. The cost of manufactured products includes direct material, direct labour and a proportion of manufacturing overheads based on normal operating capacity. (g) Plant and Equipment Each class of plant and equipment is carried at cost less, where applicable, any accumulated depreciation and any accumulated impairment loss. Plant and Equipment Plant and equipment is measured on a cost basis. dorsaVi Annual Report 2018 34 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Depreciation The depreciable amount of all fixed assets is depreciated over their estimated useful lives commencing from the time the asset is held ready for use. Class of Fixed Asset Testing equipment at cost Leased devices at cost Office equipment at cost Furniture, fixtures and fittings at cost Tooling at cost Depreciation Rates 10-67% 20% 10-67% 10-20% 10% Depreciation Basis Diminishing value Straight line Diminishing value Diminishing value Straight line (h) Leases Leases are classified at their inception as either operating or finance leases based on the economic substance of the agreement so as to reflect the risks and benefits incidental to ownership. Operating Leases Lease payments for operating leases are recognised as an expense on a straight-line basis over the term of the lease. (i) Intangibles Goodwill Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identifiable or separately recognised. Goodwill is not amortised but is tested annually for impairment, or more frequently if events or changes in circumstances indicate that it might be impaired. Goodwill is carried at cost less any accumulated impairment losses. Patents Patents, trademarks and licenses are recognised at cost and depreciated on a straight-line basis over their effective lives, which is estimated to be 20 years. Research Expenditure on research activities is recognised as an expense when incurred. Development Development costs are capitalised when the entity can demonstrate all of the following: The technical feasibility of completing the asset so that it will be available for use or sale; the intention to complete the asset and use or sell it; the ability to use or sell the asset; how the asset will generate probable future economic benefits; the availability of adequate technical, financial and other resources to complete the development and to use or sell the asset; and the ability to measure reliably the expenditure attributable to the asset during its development. Capitalised development expenditure is carried at cost less any accumulated amortisation and any accumulated impairment losses. Amortisation is calculated using a straight-line method to allocate the cost of the intangible asset over its estimated useful life, which range from 5 to 10 years. Amortisation commences when the intangible asset is available for use. Other development expenditure is recognised as an expense when incurred. (j) Impairment of Non-Financial Assets Goodwill, intangible assets not yet ready for use and intangible assets with indefinite useful lives are not subject to amortisation and are therefore tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. For impairment assessment purposes, assets are generally grouped at the lowest levels for which there are largely independent cash flows - Cash Generating Units (CGU). Accordingly, most assets are tested for dorsaVi Annual Report 2018 35 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 impairment at the cash-generating unit level. Because it does not generate cash flows independently of other assets or groups of assets, goodwill is allocated to the CGU or units that are expected to benefit from the synergies arising from the business combination that gave rise to the goodwill. Assets other than goodwill, intangible assets not yet ready for use and intangible assets with indefinite useful lives are assessed for impairment whenever events or circumstances arise that indicate the asset may be impaired. An impairment loss is recognised when the carrying amount of an asset or CGU exceeds the asset’s or CGU’s recoverable amount. The recoverable amount of an asset or CGU is defined as the higher of its fair value less costs to sell and value in use. Refer to Note 2 for a description of how management determines value in use. Impairment losses in respect of individual assets are recognised immediately in profit or loss unless the asset is carried at a revalued amount such as property, plant and equipment, in which case the impairment loss is treated as a revaluation decrease in accordance with the applicable Standard. Impairment losses in respect of CGU’s are allocated first against the carrying amount of any goodwill attributed to the CGU with any remaining impairment loss allocated on a pro rata basis to the other assets comprising the relevant CGU. (k) Income Tax Current income tax expense or revenue is the tax payable on the current period's taxable income based on the applicable income tax rate adjusted by changes in deferred tax assets and liabilities. Current Income Tax expense or revenue incudes refundable research and development tax offsets. Deferred Tax Balances Deferred tax assets and liabilities are recognised for temporary differences at the applicable tax rates when the assets are expected to be recovered or liabilities are settled. Deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction, other than a business combination, that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity. Tax Consolidation dorsaVi Ltd (parent entity) and its wholly owned subsidiary, (Australian Workplace Compliance Pty Ltd), have applied tax consolidation legislation and formed a tax-consolidated group from 1 July 2014. The parent entity and subsidiary in the tax-consolidated group have entered into a tax funding agreement such that each entity in the tax-consolidated group recognises the assets, liabilities, expenses and revenues in relation to its own transactions, events and balances only. This means that: ▪ The parent entity recognises all current and deferred tax amounts relating to its own transactions, events and balances only; ▪ The subsidiary recognises current or deferred tax amounts arising in respect of their own transactions, events and balances; ▪ Current tax liabilities and deferred tax assets arising in respect of tax losses, are transferred from the subsidiary to the head entity as inter-company payables or receivables. The tax-consolidated group also has a tax sharing agreement in place to limit the liability of the subsidiary in the tax-consolidated group arising under the joint and several liability requirements of the tax consolidation system, in the event of default by the parent entity to meet its payment obligations. (l) Provision Provisions are recognised when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. dorsaVi Annual Report 2018 36 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (m) Employee Benefits (i) Short-Term Employee Benefit Obligations Liabilities arising in respect of wages and salaries, annual leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured at the amounts based on remuneration rates which are expected to be paid when the liability is settled. The expected cost of short- term employee benefits in the form of compensated absences such as annual leave is recognised in the provision for employee benefits. All other short-term employee benefit obligations are presented as payables. (ii) Long-Term Employee Benefit Obligations The provision for employee benefits in respect of long service leave and annual leave which, are not expected to be settled within twelve months of the reporting date, are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. Employee benefit obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting date, regardless of when the actual settlement is expected to occur. (iii) Retirement Benefit Obligations Defined Contribution Superannuation Plan The Group makes contributions to defined contribution superannuation plans in respect of employee services rendered during the year. These superannuation contributions are recognised as an expense in the same period when the employee services are received. (iv) Share-Based Payments The Group operates share-based payment employee share and option schemes. The fair value of the equity to which employees become entitled is measured at grant date and recognised as an expense over the vesting period, with a corresponding increase to an equity account. The fair value of shares is measured at the market bid price at grant date. In respect of share-based payments that are dependent on the satisfaction of performance conditions, the number of shares and options expected to vest is reviewed and adjusted at each reporting date. The amount recognised for services received as consideration for these equity instruments granted is adjusted to reflect the best estimate of the number of equity instruments that eventually vest. (v) Bonus Plan The Group recognises a provision when a bonus is payable in accordance with the employee’s contract of employment, and the amount can be reliably measured. (n) Borrowing Costs Borrowing costs can include interest expense calculated using the effective interest method, finance charges in respect of finance leases, and exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs. Borrowing costs are expensed as incurred. (o) Financial Instruments Classification The Group classifies its financial instruments in the following categories: Financial assets at fair value through profit or loss, loans and receivables, held-to-maturity investments, and available-for-sale financial assets. The classification depends on the purpose for which the instruments were acquired. Management determines the classification of its financial instruments at initial recognition. dorsaVi Annual Report 2018 37 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Loans and Receivables Loans and receivables are measured at fair value at inception and subsequently at amortised cost using the effective interest rate method. Financial Liabilities Financial liabilities include trade payables, other creditors, loans from third parties and loans or other amounts due to director-related entities. Non-derivative financial liabilities are recognised at amortised cost, comprising original debt less principal payments and amortisation Financial liabilities are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Impairment of Financial Assets Financial assets are tested for impairment at each financial year end to establish whether there is any objective evidence for impairment. For loans and receivables, impairment loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset’s original effective interest rate. The amount of the loss reduces the carrying amount of the asset and is recognised in profit or loss. The impairment loss is reversed through profit or loss if the amount of the impairment loss decreases in a subsequent period and the decrease can be related objectively to an event occurring after the impairment was recognised. (p) Foreign Currency Translations and Balances Functional and Presentation Currency The financial statements of each entity within the Group are measured using the currency of the primary economic environment in which that entity operates (the functional currency). The consolidated financial statements are presented in Australian dollars which is the Group’s functional and presentation currency. Transactions and Balances Transactions in foreign currencies of entities within the consolidated group are translated into functional currency at the rate of exchange ruling at the date of the transaction. Foreign currency monetary items that are outstanding at the reporting date (other than monetary items arising under foreign currency contracts where the exchange rate for that monetary item is fixed in the contract) are translated using the spot rate at the end of the financial year. Except for certain foreign currency hedges, all resulting exchange differences arising on settlement or re-statement are recognised as revenues and expenses for the financial year. Foreign Subsidiaries Entities that have a functional currency different to the presentation currency are translated as follows: ▪ Assets and liabilities are translated at the closing rate on reporting date; ▪ Income and expenses are translated at actual exchange rates or average exchange rates for the period, where appropriate; and ▪ All resulting exchange differences are recognised in other comprehensive income. (q) Goods and Services Tax (GST) Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Tax Office. In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST. dorsaVi Annual Report 2018 38 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. (r) Comparatives Where necessary, comparative information has been reclassified and repositioned for consistency. (s) Rounding of Amounts In accordance with ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2016/191, the amounts in the directors’ report and in the financial statements have been rounded to the nearest dollar. (t) Accounting Standards Issued but not yet Effective at 30 June 2018 The AASB has issued a number of new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods, some of which are relevant to the Group. The Group has decided not to early adopt any of these new and amended pronouncements. The Group’s assessment of the new and amended pronouncements that are relevant to the Group but applicable in future reporting periods is set out below. — AASB 9: Financial Instruments (December 2014), (applicable for annual reporting periods commencing on or after 1 January 2018). These Standards will replace AASB 139: Financial Instruments: Recognition and Measurement. Key changes that may affect the Group on application of AASB 9 and associated amending Standards include: — Simplifying the general classifications of financial assets into those carried at amortised cost and those carried at fair value; — Permitting entities to irrevocably elect on initial recognition to present gains and losses on an equity instrument that is not held for trading in other comprehensive income (OCI); — Simplifying the requirements for embedded derivatives, including removing the requirements to separate and fair value embedded derivatives for financial assets carried at amortised cost; — Introducing a new model for hedge accounting that permits greater flexibility in the ability to hedge risk, particularly with respect to non-financial items; and — Requiring impairment of financial assets carried at amortised cost to be based on an expected loss approach. The adoption of AASB 9 is not expected to have on initial application a material impact on the Group’s financial statements. — AASB 15: Revenue from Contracts with Customer (applicable for annual reporting periods commencing on or after 1 January 2018). AASB 15 will provide (except in relation to some specific exceptions, such as lease contracts and insurance contracts) a single source of accounting requirements for all contracts with customers, thereby replacing all current accounting pronouncements on revenue. These Standards provide a revised principle for recognising and measuring revenue. Under AASB 15, revenue is recognised in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the provider of the goods or services expects to be entitled. To give effect to this principle, AASB 15 requires the adoption of the following 5-step model: 1. Identify the contract(s) with a customer; 2. Identify the performance obligations under the contract(s); 3. Determine the transaction price; 4. Allocate the transaction price to the performance obligations under the contract(s); and 5. Recognise revenue when (or as) the entity satisfies the performance obligations. dorsaVi Annual Report 2018 39 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 AASB 15 also provides additional guidance to assist entities in applying the revised principle to licences of intellectual property, warranties, rights of return, principal/agent considerations and options for additional goods and services. The adoption of AASB 15 is not expected to have on initial application a material impact on the Group’s financial statements. — AASB 16: Leases (applicable for annual reporting periods commencing on or after 1 January 2019). AASB 16 will replace AASB 117: Leases and introduces a single lessee accounting model that will require a lessee to recognise right-of-use assets and lease liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value. Right-of-use assets are initially measured at their cost and lease liabilities are initially measured on a present value basis. Subsequent to initial recognition: — Right-of-use assets are accounted for on a similar basis to non-financial assets, whereby the right-of-use asset is accounted for in accordance with a cost model unless the underlying asset is accounted for on a revaluation basis, in which case if the underlying asset is: ▪ Investment property, the lessee applies the fair value model in AASB 140: Investment Property to the right-of-use asset; or ▪ Property, plant or equipment, the lessee can elect to apply the revaluation model in AASB 116: Property, Plant and Equipment to all of the right-of-use assets that relate to that class of property, plant and equipment; and — Lease liabilities are accounted for on a similar basis as other financial liabilities, whereby interest expense is recognised in respect of the liability and the carrying amount of the liability is reduced to reflect lease payments made. AASB 16 substantially carries forward the lessor accounting requirements in AASB 117. Accordingly, under AASB 16 a lessor would continue to classify its leases as operating leases or finance leases subject to whether the lease transfers to the lessee substantially all of the risks and rewards incidental to ownership of the underlying asset and would account for each type of lease in a manner consistent with the current approach under AASB 117. The adoption of AASB 16 is not expected to have on initial application a material impact on the Group’s financial statements. — AASB 2016-5: Amendments to Australian Accounting Standards – Classification and Measurement of Share-based Payment Transactions (applicable for annual reporting periods commencing on or after 1 January 2018). This Amending Standard amends AASB 2: Share-based Payment to address: — The accounting for the effects of vesting and non-vesting conditions on the measurement of cash- settled share-based payments; — The classification of share-based payment transactions with a net settlement feature for withholding tax obligations; and — The accounting for a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. This Standard is not expected to significantly impact the Group’s financial statements. — AASB Interpretation 22: Foreign Currency Transactions and Advance Consideration (applicable for annual reporting periods commencing on or after 1 January 2018). Interpretation 22 clarifies that, in applying AASB 121: The Effects of Changes in Foreign Exchange Rates, the date of the transaction for the purpose of determining the exchange rate to use on initial recognition of the related asset, expense or income (or part of it) is the date on which an entity initially recognises the non-monetary asset or non-monetary liability arising from the payment or receipt of advance consideration. Accordingly, if there are multiple payments or receipts in advance, the entity is required to determine a date of the transaction for each payment or receipt of advance consideration. This Interpretation is not expected to significantly impact the Group’s financial statements. — AASB Interpretation 23: Uncertainty over Income Tax Treatments (applicable for annual reporting periods commencing on or after 1 January 2019). Interpretation 23 clarifies how to apply the recognition and measurement requirements in AASB 112: Income Taxes when there is uncertainty over income tax treatments. To this end, Interpretation 23 requires: dorsaVi Annual Report 2018 40 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 — — — — — An entity to consider whether each uncertain tax treatment should be considered separately or together with one or more other uncertain tax treatments based on which approach better predicts the resolution of the uncertainty; In assessing whether and how an uncertain tax treatment affects the determination of taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates, assume that the taxation authority will examine amounts it has a right to examine and have full knowledge of all related information when making those examinations; If the entity concludes that it is probable that the taxation authority will accept the uncertain tax treatment, the entity will determine current tax and deferred tax consistently with the treatment used or planned to be used in its income tax filings; If the entity concludes that it is not probable that the taxation authority will accept an uncertain tax treatment, the entity reflects the effect of uncertainty in the determination of current tax and deferred tax, based on either the ‘most likely’ amount or the ‘probability-weighted’ amount of tax (depending on which method the entity expects to better predict the resolution of the uncertainty); and An entity to reassess a judgement or estimate required under Interpretation 23 if the facts and circumstances on which the judgement or estimate was based change or as a result of new information that affects the judgement or estimate. This Interpretation is not expected to significantly impact the Group’s financial statements. NOTE 2: SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS Certain accounting estimates include assumptions concerning the future, which, by definition, will seldom represent actual results. Estimates and assumptions based on future events have a significant inherent risk, and where future events are not as anticipated there could be a material impact on the carrying amounts of the assets and liabilities discussed below: (a) Impairment of Non-Financial Assets other than Goodwill All assets are assessed for impairment at each reporting date by evaluating whether indicators of impairment exist in relation to the continued use of the asset by the Group. Impairment triggers include declining product or manufacturing performance, technology changes, adverse changes in the economic or political environment or future product expectations. If an indicator of impairment exists, the recoverable amount of the asset is determined. The recoverable amount of a CGU is based on value in use calculations. The Directors have determined that there is one CGU applicable to the cash flows generated. Value in use calculations are based on projected cash flows approved by management covering a maximum five-year period. Management’s determination of cash flow projections are based on past performance and its expectations of the future. The present value of future cash flows used to determine value in use have been calculated using: An average growth rate of 30% for years two to five and which is based on historical experience; a terminal value growth rate of 3% and a discount rate of 16%. (b) Income Tax Deferred tax assets and liabilities are based on the assumption that no adverse change will occur in the income tax legislation and the anticipation that the Group will derive sufficient future assessable income to enable the benefit to be realised and comply with the conditions of deductibility imposed by the law. Deferred tax assets are recognised for deductible temporary differences as management considers that it is probable that future taxable profits will be available to utilise those temporary differences. (c) Employee Benefits The calculation of long term employment benefits requires estimation of the retention of staff, future wage levels and timing of the settlement of employee entitlements. The estimates are based on historical trends. (d) Share Based Payments Calculation of share-based payments requires estimation of the timing of the exercise of the underlying equity instrument. The estimates are based on historical trends. dorsaVi Annual Report 2018 41 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 NOTE 3: FINANCIAL RISK MANAGEMENT The Group is exposed to a variety of financial risks comprising: Interest rate risk ▪ Currency risk ▪ ▪ Credit risk ▪ Liquidity risk The Board of directors has overall responsibility for identifying and managing operational and financial risks. The Group holds the following financial instruments: Financial assets Cash and cash equivalents Trade receivables Other receivables Related party receivables Finance liabilities Trade payables Related party payables Other payables (a) Currency Risk 2018 $ 3,966,857 1,164,759 1,024,320 - 6,155,936 228,901 - 855,743 1,084,644 2017 $ 8,609,602 1,490,542 893,466 26,607 11,020,217 304,012 1,000 625,072 930,084 Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group is exposed to foreign currency risk through the operation of wholly owned subsidiaries in the United Kingdom and the United States of America. Whilst operations in these geographical regions are in their infancy, the Group has not established a hedging policy to mitigate adverse currency risk. Sensitivity If foreign exchange rates were to increase/decrease by 10% from rates used to determine fair values of all financials instruments as at the reporting date, assuming all other variables that might impact on fair value remain constant, then the impact on loss for the year and equity is as follows: +/- 100 basis points Impact on loss after tax Impact on equity 2018 $ 141,422 141,422 2017 $ 121,637 121,637 dorsaVi Annual Report 2018 42 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (b) Interest Rate Risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate as a result of changes in market interest rates. The Group’s exposure to interest rate risk in relation to future cash flows and the effective weighted average interest rates on classes of financial assets and financial liabilities, is as follows: 2018 Financial Instruments Financial assets Cash Flexi Deposit Term Deposit Term Deposit Trade receivables Other receivables Financial liabilities Trade payables Other payables 2017 Financial Instruments Financial assets Cash Flexi Deposit Floating Deposit Term Deposit Term Deposit Trade receivables Other receivables Related party receivables Financial liabilities Trade payables Other payables Related party payables Interest Bearing $ 1,891,314 2,000,000 26,602 48,941 - - 3,966,857 Non-interest bearing $ - - - - 1,164,759 1,024,320 2,189,079 Total carrying amount $ 1,891,314 2,000,000 26,602 48,941 1,164,759 1,024,320 6,155,936 Weighted average effective interest rate 0.80% Floating 2.59% Fixed 2.52% Fixed 2.09% Fixed 0.00% 0.00% - - - 228,901 855,743 1,084,644 228,901 855,743 1,084,644 0.00% 0.00% 0.00% Interest Bearing $ 2,534,495 3,500,000 2,500,000 26,602 48,505 - - - 8,609,602 - - - - Non-interest bearing $ - - - - - 1,490,542 893,466 26,607 2,410,615 304,012 625,072 1,000 930,084 Total carrying amount $ 2,534,495 3,500,000 2,500,000 26,602 48,505 1,490,542 893,466 26,607 11,020,217 304,012 625,072 1,000 930,084 Weighted average effective interest rate 1.50% Floating 2.55% Fixed 2.47% Floating 2.65% Fixed 2.10% Fixed 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% No other financial assets or financial liabilities are expected to be exposed to interest rate risk. There are no variable interest borrowings in the Group. The Group is exposed to variable interest cash and cash deposits held; however, fluctuations due to interest rates are considered immaterial. dorsaVi Annual Report 2018 43 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (c) Credit Risk Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The maximum exposure to credit risk, excluding the value of any collateral or other security, at balance date of recognised financial assets is the carrying amount of those assets, net of any provisions for impairment of those assets, as disclosed in consolidated statement of financial position and notes to the consolidated financial statements. The Group does not have any material credit risk exposure to any single debtor or group of debtors under financial instruments entered into by the Group. The Group minimises concentrations of credit risk in relation to trade receivables by undertaking transactions with a number of known and existing customers and reputable organisations. (i) Cash Deposits Credit risk for cash deposits is managed by holding all cash deposits with major Australian banks. (ii) Trade Receivables Credit risk for trade receivables is managed by setting credit limits and completing credit checks for new customers. Outstanding receivables are regularly monitored for payment in accordance with credit terms. The ageing analysis of trade and other receivables is provided in Note 9. As the Group undertakes transactions with a large number of customers and regularly monitors payment in accordance with credit terms, the financial assets that are neither past due nor impaired, are expected to be received in accordance with the credit terms. (iii) Other Receivables Other receivables relate to research and development tax concessions receivable from the Australian Taxation Office and do not pose a material credit risk. (d) Liquidity Risk The Group’s approach to managing liquidity risk is to ensure, as far as possible, that, at all times, it has sufficient liquidity to meet its liabilities. The Group has cash reserves and expects to settle all financial liabilities within six months of year end. (e) Fair Value The fair value of financial assets and financial liabilities approximates their carrying amounts as disclosed in the consolidated statement of financial position and notes to the consolidated financial statements. NOTE 4: REVENUE AND OTHER INCOME Revenue from continuing operations Device and consumables sales Device rental income Consulting income Other income Grant income Interest income Foreign exchange gain 2018 $ 2017 $ 927,232 663,705 1,842,411 3,433,348 347,051 112,182 501,690 960,923 4,394,271 981,378 573,558 1,911,091 3,466,027 258,370 148,588 24,897 431,855 3,897,882 dorsaVi Annual Report 2018 44 NOTE 5: LOSS FROM CONTINUING OPERATIONS Losses before income tax has been determined after: Cost of sales Write-off of goodwill Depreciation Amortisation of patents and intangibles Employee benefits expense - Share based payments - Other employee benefits Operating lease rental Research and development expense NOTE 6: INCOME TAX (a) Current tax Components of Tax Benefit Prima Facie Tax Payable (b) The prima facie tax refundable on loss before income tax is reconciled to the income tax benefit as follows: Prima facie income tax refundable on loss before income tax at 27.5% (2017: 30%) Add tax effect of: - Accounting research and development expenditure - Other non-allowable items - Write-off of goodwill - Share based payments expense - Tax losses not recognised - Unrealised foreign exchange loss - Deferred tax assets not recognised Less tax effect of: - Amortisation of capital raising costs - Research and development tax offset - Unrealised foreign exchange gain - Effect of foreign tax rates - Deferred tax assets not recognised Income tax benefit attributable to loss Deferred Tax Assets not brought to Account (c) Temporary differences Operating tax losses NOTE 7: DIVIDENDS There were no dividends paid during the period. dorsaVi Ltd and controlled entities ABN: 15 129 742 409 2018 $ 2017 $ 873,625 112,110 117,342 620,939 447,431 4,050,885 4,498,316 356,250 2,052,485 1,068,139 - 91,916 82,761 371,121 3,931,522 4,302,643 283,078 1,845,839 (913,671) (841,199) (1,276,205) (1,415,234) 545,686 1,215 30,830 123,043 935,847 - - 1,636,621 115,905 913,671 138,136 101,090 5,285 1,274,087 (913,671) 175,325 6,412,609 6,587,934 553,752 9,252 - 111,336 720,753 152,728 73,713 1,621,534 127,044 841,199 - 79,256 - 1,047,499 (841,199) 183,283 5,534,457 5,717,740 dorsaVi Annual Report 2018 45 NOTE 8: CASH AND CASH EQUIVALENTS Cash at bank and on hand Deposits at call NOTE 9: RECEIVABLES CURRENT Trade receivables Provision for doubtful debts Accrued income R&D tax offset refundable Amounts receivable from: - Superspine Forrest Hill Unit Trust dorsaVi Ltd and controlled entities ABN: 15 129 742 409 2018 $ 1,891,314 2,075,543 3,966,857 1,245,737 (80,978) 1,164,759 139,845 884,475 1,024,320 2017 $ 2,534,495 6,075,107 8,609,602 1,571,003 (80,461) 1,490,542 52,022 841,444 893,466 - 2,189,079 26,607 2,410,615 Trade receivables ageing analysis at 30 June is: Not past due Past due 31-60 days Past due 61-90 days Past due more than 90 days Gross 2018 $ 560,017 458,572 40,078 187,070 1,245,737 Impairment 2018 $ - - - (80,978) (80,978) Gross 2017 $ 1,091,650 133,331 204,391 141,631 1,571,003 Impairment 2017 $ - - - (80,461) (80,461) Trade receivables are non-interest bearing with 30-day terms. An impairment loss is recognised when there is objective evidence that an individual trade receivable is impaired. Trade receivables not impaired are expected to be received. NOTE 10: INVENTORIES CURRENT At cost Finished goods NOTE 11: OTHER ASSETS 2018 $ 2017 $ 324,934 317,157 Prepayments 235,995 146,125 NOTE 12: INTANGIBLE ASSETS Patents at cost Less accumulated amortisation Intangibles at cost Less accumulated amortisation Goodwill at cost 934,156 (147,581) 3,732,206 (634,528) - 3,884,253 745,402 (105,462) 1,910,856 (55,707) 112,110 2,607,199 dorsaVi Annual Report 2018 46 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (a) Reconciliations Reconciliation of the carrying amounts of intangible assets at the beginning and end of the current financial year: Goodwill Patents Intangibles 2018 $ 2017 $ 2018 $ 2017 $ 2018 $ 2017 $ Opening balance Additions Amortisation expense/write-off Closing balance 112,110 - (112,110) - 112,110 - - 112,110 639,940 188,753 (42,118) 786,575 525,701 148,318 (34,079) 639,940 1,855,149 1,821,350 (578,821) 3,097,678 422,060 1,481,771 (48,682) 1,855,149 Additions to intangibles during the year related to product that had progressed from the research phase to where it has been determined that the product will be developed for progressive release to the market (refer Note 1 (i)). During the year workplace compliance services ceased to be provided and as a result goodwill was written off. NOTE 13: PLANT AND EQUIPMENT 2018 $ 2017 $ Plant and Equipment Testing equipment at cost Accumulated depreciation Leased devices at cost Accumulated depreciation Office equipment at cost Accumulated depreciation Furniture, fixtures and fittings at cost Accumulated depreciation Tooling at cost Accumulated depreciation Total plant and equipment 128,635 (108,314) 20,321 267,743 (158,657) 109,086 252,268 (176,043) 76,225 63,691 (11,097) 52,594 94,258 (28,153) 66,105 324,331 126,485 (84,997) 41,488 257,144 (106,553) 150,591 231,166 (147,862) 83,304 63,691 (5,215) 58,476 67,530 (20,295) 47,235 381,094 dorsaVi Annual Report 2018 47 (a) Reconciliations Reconciliation of the carrying amounts of plant and equipment at the beginning and end of the current financial year: dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Testing equipment Opening carrying amount Additions Depreciation expense Closing carrying amount Leased devices Opening carrying amount Transfers from inventory Depreciation expense Closing carrying amount Office equipment Opening carrying amount Additions Depreciation expense Closing carrying amount Furniture, fixtures and fittings Opening carrying amount Additions Depreciation expense Closing carrying amount Tooling Opening carrying amount Additions Depreciation expense Closing carrying amount Total plant and equipment Opening carrying amount Additions Transfers from inventory Depreciation expense Closing carrying amount NOTE 14: PAYABLES CURRENT Unsecured liabilities Trade payables Unearned income Sundry creditors and accruals Loan from related parties 2018 $ 41,488 2,150 (23,317) 20,321 150,591 10,599 (52,104) 109,086 83,304 21,102 (28,181) 76,225 58,476 - (5,882) 52,594 47,235 26,728 (7,858) 66,105 381,094 49,980 10,599 (117,342) 324,331 228,901 579,434 276,309 - 1,084,644 2017 $ 39,042 18,500 (16,054) 41,488 168,672 29,276 (47,357) 150,591 64,449 40,264 (21,409) 83,304 6,920 53,147 (1,591) 58,476 31,159 21,581 (5,505) 47,235 310,242 133,492 29,276 (91,916) 381,094 304,012 229,571 395,501 1,000 930,084 dorsaVi Annual Report 2018 48 NOTE 15: PROVISIONS CURRENT Employee benefits NON-CURRENT Employee benefits (a) Aggregate employee benefits liability (b) Number of employees at year end NOTE 16: SHARE CAPITAL The Group’s share capital is as follows: dorsaVi Ltd and controlled entities ABN: 15 129 742 409 2018 $ 2017 $ 381,782 385,696 41,858 30,340 423,640 34 416,036 41 Ordinary Shares Parent Equity 2018 Parent Equity 2017 No of Shares $ No of Shares $ Beginning of the financial year Issued during the financial year - Employee share scheme (i) - Other shares issued (ii) - Shares issued (iii) - Cost of raising capital 167,305,859 38,440,518 149,914,616 30,709,796 612,363 - - - - 14,706 - - - - 17,391,243 - - 40,161 7,999,972 (309,411) End of the financial year 167,918,222 38,455,224 167,305,859 38,440,518 (i) Shares Issued under the Employee Share Ownership Plan: During the year performance rights previously granted to employees under the Employee Share Ownership Plan (ESOP) vested into shares. The shares were issued for $Nil consideration. (ii) Other Shares Issued: During the year a number of employees, previously issued shares under the ESOP repaid their non-recourse loans and took possession of their share entitlement. (iii) Shares Issued in a Capital Raising: There was no capital raising during the year ended 30 June 2018. In the prior year, the Group: ▪ ▪ ▪ Issued 10,869,565 fully paid ordinary shares to institutional and sophisticated investors at $0.46 per share raising $5,000,000 before costs; Issued 4,347,828 fully paid ordinary shares to major shareholder, Starfish Technology Fund II Trust A and Starfish Technology Fund II Trust B, at $0.46 per share raising $2,000,001; and Issued 2,173,850 fully paid ordinary shares under a share purchase plan to shareholders at $0.46 per share raising $999,971. dorsaVi Annual Report 2018 49 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Rights of each Type of Share Ordinary shares participate in dividends and the proceeds on winding up of the parent entity in proportion to the number of shares held. At shareholders’ meetings, each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands. Capital Management When managing capital, management's objective is to ensure the Group continues as a going-concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders. This is achieved through the monitoring of historical and forecast performance and cash flows. During 2018, management paid dividends of $Nil (2017: $Nil). Employee Share Ownership Plan (ESOP) The Group continued to offer employee participation in short-term and long-term incentive schemes as part of the remuneration packages for the employees of the Group. Refer to Note 21, Share Based Payments, for detailed disclosures. NOTE 17: RESERVES AND ACCUMULATED LOSSES Share-based payment reserve Foreign currency translation reserve Notes 17(a) 17(b) 2018 $ 1,000,854 (269,447) 731,407 2017 $ 584,162 174,124 758,286 Accumulated losses 17(c) (29,769,466) (26,073,132) (i) Nature and Purpose of Reserve This reserve is used to record the fair value of options and shares issued to employees as part of their remuneration. The balance is transferred to share capital when options are granted and the balance is transferred to retained earnings when options lapse. (ii) Movements in Reserve Share-based Payment Reserve (a) Balance at beginning of year Movement taken to comprehensive income during the year: - Employee share ownership plan - Equity instruments lapsed Balance at end of year Foreign Currency Translation Reserve (b) Balance at beginning of year Movement taken to comprehensive income during the year Balance at end of year (c) Accumulated Losses Balance at beginning of year Net loss attributable to members of dorsaVi Ltd Reversal of share-based payment reserve Balance at end of year 584,162 228,367 447,431 (30,739) 1,000,854 174,124 (443,571) (269,447) 371,121 (15,326) 584,162 (134,871) 308,995 174,124 (26,073,132) (3,727,073) 30,739 (29,769,466) (22,212,210) (3,876,248) 15,326 (26,073,132) dorsaVi Annual Report 2018 50 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (a) Reconciliation of Cash Cash at the end of the financial year as shown in the statement of cash flows is reconciled to the related items in the statement of financial position as follows: NOTE 18: CASH FLOW INFORMATION Cash at bank and on hand Deposits at call 2018 $ 1,891,314 2,075,543 3,966,857 2017 $ 2,534,495 6,075,107 8,609,602 (b) Reconciliation of Cash Flow used in Operations with Loss after Income Tax Loss from ordinary activities after income tax (3,727,073) (3,876,248) Adjustments and Non-cash Items Amortisation Depreciation Write-off of goodwill Share based payments Movement in debtor provision Foreign currency translation through reserve Changes in Assets and Liabilities (Increase) / decrease in receivables (Increase) / decrease in other assets Increase in inventories Increase in payables (Increase) in research and development tax offset receivable Increase in provisions Cash flows used in operating activities NOTE 19: COMMITMENTS AND CONTINGENCIES 620,939 117,342 112,110 447,431 517 (443,571) 325,266 (151,086) (18,376) 154,560 (43,031) 7,604 1,129,705 (2,597,368) 82,761 91,916 - 371,121 61,830 308,995 (563,110) 64,533 (99,655) 216,082 (162,979) 118,030 489,524 (3,386,724) Operating Lease Commitments (a) Non-cancellable operating leases contracted for but not capitalised in the financial statements: Payable - Not later than one year - Later than one year and not later than five years 28,862 - 28,862 138,521 1,575 140,096 Description of Leasing Arrangement: - Operating lease - premises in Australia - Month by month Agreement - Operating lease - storage in Australia - Expires 18 November 2018 - Operating lease - premises in Europe - Expires 30 September 2018 Capital Expenditure Commitments (b) Acquisition of intangible asset Total capital expenditure commitments - - 170,000 170,000 Contingent Asset and Liabilities (c) There are no contingent assets or contingent liabilities at balance date. dorsaVi Annual Report 2018 51 NOTE 20: LOSS PER SHARE Reconciliation of loss used in calculating loss per share: Loss from continuing operations Loss used in calculating basic loss per share Loss used in calculating diluted loss per share dorsaVi Ltd and controlled entities ABN: 15 129 742 409 2018 $ 2017 $ (3,727,073) (3,727,073) (3,727,073) (3,876,248) (3,876,248) (3,876,248) 2018 2017 No of Shares No of Shares Weighted average number of ordinary shares used in calculating basic earnings per share Effect of dilutive securities: Equity instruments Adjusted weighted average number of ordinary shares used in calculating diluted earnings per share 167,773,817 - - 158,497,079 - - 167,773,817 158,497,079 NOTE 21: SHARE BASED PAYMENTS (a) Employee Shares The Board established an Employee Share Ownership Plan (ESOP). This plan was established by the Group to facilitate the acquisition of Shares, Options and Performance Rights by those employed, or otherwise engaged by, or holding a position of office in, dorsaVi. They key objective of the plan is to provide an incentive for employees to align their interests with those of the shareholders. Other objectives of the ESOP include: ▪ To attract, motivate and retain quality employees and Directors of dorsaVi; ▪ To create a commitment and united purpose between the employees and Directors and dorsaVi; and ▪ To add wealth for all shareholders of dorsaVi through the motivation of dorsaVi’s employees and Directors. This plan allows for dorsaVi to offer employees non-recourse and interest-free loans to acquire fully paid shares. On 20 September 2013, the Group’s shareholders approved the giving of such financial assistance. Only a person who is an Eligible Person may be invited and authorised by the Board to participate in this plan. An Eligible person means: ▪ An employee of dorsaVi or a subsidiary of dorsaVi; or ▪ A Director of dorsaVi or a subsidiary of dorsaVi who holds a salaried employment or office in dorsaVi or a subsidiary of dorsaVi; or ▪ A contractor engaged by dorsaVi or a subsidiary of dorsaVi and whom the Group has determined is an Eligible Person to participate in this plan. There is no maximum limit on the number of Securities that may be acquired by Eligible Persons under the ESOP. However, the Board intends to restrict further issues of Securities to no more than 5% of the Group’s issued share capital. This limit will be maintained unless shareholder approval is subsequently sought to increase this level. During the year ended 30 June 2018, 612,363 ESOP shares were issued to employees at $Nil consideration on the achievement of key performance targets. No ESOP shares were issued to employees during the year ended 30 June 2017. The ESOP Shares are subject to restriction agreements imposing loan repayment obligations, and, that the holders of Shares are not able to trade them within 12 months of issuance. After 12 months, 1/3rd of the issued shares can be traded. Contingent upon continued employment with the Group and meeting loan repayment obligations, the remaining shares become available for trading at a monthly rate of 1/36th of the shares issued over the subsequent 24 months. dorsaVi Annual Report 2018 52 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 (b) Employee Options During the year ended 30 June 2018 no options to ordinary shares were granted to employees (2017: 1,300,000 options granted). During the year a total of 78,333 options were cancelled (2017: 1,977,778 options cancelled). (c) Employee Performance Rights During the period 1 July 2016 to 30 June 2017 and under the Group’s Employee Share Ownership Plan 2013, dorsaVi agreed to grant 3,749,000 performance rights that may vest into ordinary shares of the Group. Performance rights are subject to performance vesting conditions in accordance with each agreement. The performance rights do not vest into shares unless the performance conditions are met. During the year ended 30 June 2018 612,363 performance rights vested into shares (2017: Nil). The performance rights vested into shares at $Nil. During the year ended 30 June 2018 724,971 performance rights lapsed (2017: Nil). At 30 June 2018 2,411,666 performance rights remain outstanding. Details of shares, options and performance rights granted are as follows: 2018 Grant date Expiry date Exercise price Balance at 1/7/2017 Granted during the year Vested during the year Expired during the year Balance at 30/6/2018 Exercisable at the end of the year 3-Jul-19 3-Jul-14 1-Sep-19 2-Sep-14 5-Nov-14 5-Nov-19 25-Feb-15 25-Feb-20 17-Aug-15 17-Aug-20 24-Mar-16 24-Mar-21 29-Nov-16 1-Oct-17 29-Nov-16 1-Oct-18 29-Nov-16 1-Oct-19 29-Nov-16 29-Nov-19 15-May-17 15-May-22 15-May-17 1-Oct-22 15-May-17 1-Oct-23 15-May-17 1-Oct-24 15-May-17 1-Jul-24 15-May-17 1-Oct-17 15-May-17 1-Oct-18 15-May-17 1-Oct-19 15-May-17 1-Jul-19 1-Jul-17 5-Jun-17 1-Oct-17 5-Jun-17 1-Oct-18 5-Jun-17 1-Oct-19 5-Jun-17 1-Jul-19 5-Jun-17 1-Jan-18 5-Jun-17 1-Jan-19 5-Jun-17 5-Jun-17 1-Jan-20 TOTAL 250,000 $0.46 100,000 $0.40 20,000 $0.40 80,000 $0.36 500,000 $0.26 200,000 $0.40 150,000 - 150,000 - 150,000 - 450,000 - 550,000 $0.33 133,333 $0.33 133,333 $0.33 133,334 $0.33 350,000 $0.33 79,000 - 39,000 - 39,000 - 117,000 - 250,000 - 350,000 - 350,000 - 350,000 - 775,000 - 83,334 - 83,334 - - 333,332 6,199,000 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 75,000 - - - - - - - - 54,050 - - - 250,000 202,063 - - - 31,250 - - - - - - - - 75,000 - - - - 78,333 - - - 24,950 - - - - 147,937 75,000 75,000 275,000 52,084 - - 612,363 803,304 250,000 100,000 20,000 80,000 500,000 200,000 - 150,000 150,000 450,000 550,000 55,000 133,333 133,334 350,000 - 39,000 39,000 117,000 - - 275,000 275,000 500,000 - 83,334 333,332 4,783,333 250,000 100,000 20,000 80,000 500,000 100,000 - - - - 550,000 55,000 - - - - - - - - - - - - - - - 1,655,000 dorsaVi Annual Report 2018 53 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 2017 Grant Date Expiry Date Exercise Price 3-Jul-14 2-Sep-14 21-Oct-14 5-Nov-14 25-Feb-15 17-Aug-15 30-Sep-15 30-Sep-15 30-Sep-15 11-Dec-15 24-Mar-16 8-Jun-16 29-Nov-16 29-Nov-16 29-Nov-16 29-Nov-16 15-May-17 15-May-17 15-May-17 15-May-17 15-May-17 15-May-17 15-May-17 15-May-17 15-May-17 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 5-Jun-17 TOTAL 3-Jul-19 1-Sep-19 14-Jul-16 5-Nov-19 25-Feb-20 17-Aug-20 30-Sep-20 30-Sep-21 30-Sep-22 11-Dec-16 24-Mar-21 8-Jun-21 1-Oct-17 1-Oct-18 1-Oct-19 29-Nov-19 15-May-22 1-Oct-22 1-Oct-23 1-Oct-24 1-Jul-24 1-Oct-22 1-Oct-23 1-Oct-24 1-Jul-24 1-Jul-17 1-Oct-17 1-Oct-18 1-Oct-19 1-Jul-19 1-Jan-18 1-Jan-19 1-Jan-20 $0.46 $0.40 $0.40 $0.40 $0.36 $0.26 $0.28 $0.28 $0.28 $0.38 $0.40 $0.34 $0.33 $0.33 $0.33 $0.33 $0.33 - - - - - - - - - - - - - - - - Granted during the Year Balance at 1/7/2016 250,000 100,000 900,000 20,000 80,000 500,000 250,000 250,000 250,000 277,778 200,000 50,000 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 150,000 150,000 150,000 450,000 550,000 133,333 133,333 133,334 350,000 79,000 39,000 39,000 117,000 250,000 350,000 350,000 350,000 775,000 83,334 83,334 333,332 3,127,778 5,049,000 Balance at 30/6/2017 Expired during the Year Exercised during the Year 250,000 - - 100,000 - - - 900,000 - 20,000 - - 80,000 - - 500,000 - - - 250,000 - - 250,000 - - 250,000 - - 277,778 - 200,000 - - - 50,000 - 150,000 - - 150,000 - - 150,000 - - 450,000 - - 550,000 - - 133,333 - - 133,333 - - 133,334 - - 350,000 - - 79,000 - - 39,000 - - 39,000 - - 117,000 - - 250,000 - - 350,000 - - 350,000 - - 350,000 - - 775,000 - - 83,334 - - 83,334 - - 333,332 - - - 1,977,778 6,199,000 Exercisable at the end of the Year 250,000 91,666 - 20,000 80,000 500,000 - - - - 100,000 - - - - - 550,000 - - - - - - - - - - - - - - - - 1,591,666 Other additional information associated with these share performance rights and option grants include: ▪ The weighted average remaining contractual life for equity entitlements outstanding at the end of the period was 2 years. ▪ The weighted average value of the equity entitlements at grant date was $0.17. This excluded any consideration of the impact of the exercise (or vesting) conditions. ▪ The fair value was determined using the binomial tree method or the Black-Scholes option-pricing models. ▪ The share price at grant date ranged from: $0.26 to $0.46 ▪ Expected price volatility of the Group’s shares: 80% ▪ Dividends: $Nil ▪ Risk free interest rate: 1.81% to 2.50% dorsaVi Annual Report 2018 54 (c) Expenses Recognised from Share-Based Payment Transactions The expense recognised in relation to the share-based payment transactions was recorded within employee benefits expense in the statement of comprehensive income were as follows: dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Equity instruments issued under employee share plan Shares issued under employee share plan Total expenses recognised from share-based payment transactions NOTE 22: DIRECTORS' AND EXECUTIVE COMPENSATION Compensation by Category Short-term employment benefits Post-employment benefits Share-based payments 2018 $ 54,943 392,488 2017 $ 339,866 31,255 447,431 371,121 1,951,642 112,309 369,702 2,433,653 1,771,315 119,838 290,885 2,182,038 NOTE 23: SUBSIDIARIES AND RELATED PARTY DISCLOSURES The consolidated financial statements include the financial statements of dorsaVi Ltd and its controlled entities listed below: dorsaVi Europe Ltd dorsaVi USA, Inc. Australian Workplace Compliance Pty Ltd Country of incorporation Ownership interest held by DVL UK USA AUS 2018 % 100 100 100 2017 % 100 100 100 ▪ dorsaVi Europe Ltd was incorporated on 3 February 2014. ▪ dorsaVi USA, Inc. was incorporated on 19 May 2014. ▪ Australian Workplace Compliance Pty Ltd was purchased on 3 July 2014. (a) Transactions with Entities with Associates: dorsaVi Ltd sold its 25% ownership of Superspine Forrest Hill Unit Trust on 30 June 2018 and it ceased to be considered an associate of dorsaVi Ltd. The transaction was settled in full during July 2018. At 30 June 2018 there was a loan receivable from Superspine Forrest Hill Unit Trust of $Nil (2017: $26,607). There was also a loan payable at balance date for $Nil (2017: $1,000). (b) Transactions with Directors, Key Management Personnel and Other Related Parties: During the year ended 30 June 2017, dorsaVi Ltd paid $54,120 (2017: $54,120) to Starfish Technology Fund II, LP on behalf of Michael Panaccio for director’s fees. Starfish Ventures Pty Ltd is a related party as it is connected with a director of dorsaVi Ltd. During the year ended 30 June 2018, Starfish Ventures Pty Ltd charged rent to dorsaVi Ltd. Total value of these rental charges was $109,346 (2017: $121,970). The rent was charged to dorsaVi on normal terms and conditions. The balance outstanding at balance date was $15,047 (2017: $14,916) included in Trade Payables at Note 14. dorsaVi Annual Report 2018 55 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 During the nine-month period ended 11 April 2018, dorsaVi Ltd paid $70,864 (2017: $104,038) to Safety Assess Pty Ltd a related Company of Dane Heaysman. These amounts are on normal commercial terms and were paid to these parties in their capacity as ViSafe Assessors on various ViSafe projects throughout the financial year. Dane Heaysman and the company are related to dorsaVi through Dane’s relationship to his father, Mark Heaysman. Mark Heaysman ceased to be a KMP on 11 April 2018. NOTE 24: AUDITOR'S REMUNERATION Amounts Paid and Payable to Pitcher Partners Melbourne for: Audit and Other Assurance Services (i) An audit or review of the financial report of the entity and any other entity in the consolidated entity Total remuneration for audit and other assurance services Other Non-audit Services (ii) Taxation and other Compliance Services Total remuneration for non-audit services Total remuneration of Pitcher Partners Melbourne NOTE 25: PARENT ENTITY INFORMATION Summarised Statement of Financial Position (a) Assets Current assets Non-current assets Total assets Liabilities Current liabilities Non-current liabilities Total liabilities Net assets Equity Share capital Share-based payment reserve Accumulated losses Total equity 2018 $ 2017 $ 94,000 94,000 23,450 23,450 117,450 79,400 79,400 26,831 26,831 106,231 17,886,039 4,208,584 22,094,623 1,888,928 41,858 1,930,786 20,163,837 20,108,383 2,988,293 23,096,676 1,859,915 30,340 1,890,255 21,206,421 38,455,224 1,000,854 (19,292,241) 20,163,837 38,440,518 584,162 (17,818,259) 21,206,421 Summarised Statement of Comprehensive Income (b) Loss for the year Other comprehensive income for the year Total comprehensive income for the year (1,504,721) - (1,504,721) (1,964,808) - (1,964,808) dorsaVi Annual Report 2018 56 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 NOTE 26: SEGMENT INFORMATION (a) Description of Segments The Group’s chief operating decision maker has identified the following reportable segments: ▪ Segment 1: Australia; ▪ Segment 2: Europe; ▪ Segment 3: United States of America. Management differentiates operating segments based on geographical areas and regulatory environments. The type of products and services from which each reportable segment derives its revenue is considered the same. The operating segments have been identified based on internal reports reviewed by the Group’s chief operating decision makers in order to allocate resources to the segment and assess its performance. (b) Segment Information The Group’s chief operating decision maker’s use segment revenue and segment result to assess the financial performance of each operating segment. Amounts for segment information are measured in the same way in the financial statements. They include items directly attributable to the segment and those that can reasonably be allocated to the segment based on the operations of the segment. There has been no inter-segment revenue during the year. Segment information is reconciled to financial statements and underlying profit disclosure notes as follows: 2018 Segment revenue Total segment revenue Segment revenue from external source Segment result Total segment result Segment result from external source Items included within the segment result: Grant income Interest income Foreign exchange gain Depreciation and amortisation expense Write-off of goodwill Income tax benefit Total Segment Assets Elimination Consolidated segment assets Total assets include: Additions to non-current assets Total Segment Liabilities Elimination Consolidated segment liabilities Australia $ Europe $ USA $ Total $ 2,415,744 2,415,744 725,568 725,568 1,252,959 1,252,959 4,394,271 4,394,271 (1,504,721) (1,504,721) (833,018) (1,389,334) (833,018) (1,389,334) (3,727,073) (3,727,073) 347,051 112,172 501,690 (738,281) (112,110) 892,831 22,336,064 - 10 - - - 20,840 689,731 - - - - - - 912,263 2,060,083 (2,010,059) - - (4,035,731) (8,475,103) 347,051 112,182 501,690 (738,281) (112,110) 913,671 23,938,058 (13,012,609) 10,925,449 2,060,083 (14,520,893) 13,012,609 (1,508,284) dorsaVi Annual Report 2018 57 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 2017 Australia $ Europe $ USA $ Total $ Segment Revenue Total Segment Revenue Segment Revenue from External Source Segment Result Total Segment Result Segment Result from External Source 2,037,596 2,037,596 675,438 675,438 1,184,848 1,184,848 3,897,882 3,897,882 (1,964,808) (1,964,808) (468,145) (1,443,295) (468,145) (1,443,295) (3,876,248) (3,876,248) Items included within the Segment Result: Grant Income Interest Income Depreciation and Amortisation Expense Income Tax Benefit 258,370 148,564 (174,677) 802,940 - 24 - 38,259 - - - - Total Segment Assets Elimination Consolidated Segment Assets Total Assets include: Additions to Non-current Assets Total Segment Liabilities Elimination Consolidated Segment Liabilities (c) Major Customers 23,338,117 1,031,158 1,044,604 1,763,581 (1,969,528) - - (3,407,529) (6,911,150) 258,370 148,588 (174,677) 841,199 25,413,879 (10,942,087) 14,471,792 1,763,581 (12,288,207) 10,942,087 (1,346,120) In 2018 and 2017 no customer contributed greater than 10% of the Group’s total revenue. NOTE 27: SUBSEQUENT EVENTS With the exception of the following, no matters or circumstances have arisen since the end of the financial year that have significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years. ▪ On 3 July 2018, dorsaVi Ltd announced that it had signed an agreement with CitiPower and Powercor for the provision of dorsaVi’s wearable sensor technology to profile movement risk and improve manual handling safety. ▪ On 18 July 2018, dorsaVi announced that it had signed an evaluation agreement with Stryker Leibinger GmbH & Co to evaluate ViMove2. dorsaVi Annual Report 2018 58 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Directors’ Declaration The directors declare that the financial statements and notes set out on pages 28 to 58 in accordance with the Corporations Act 2001: a) Comply with Accounting Standards and the Corporations Regulations 2001, and other mandatory professional reporting requirements; b) As stated in Note 1(a) the consolidated financial statements also comply with International Financial Reporting Standards; and c) Give a true and fair view of the financial position of the Group as at 30 June 2018 and of its performance for the year ended on that date. In the directors’ opinion, there are reasonable grounds to believe that dorsaVi Ltd will be able to pay its debts as and when they become due and payable. This declaration has been made after receiving the declarations required to be made by the chief executive officer and chief financial officer to the directors in accordance with section 295A of the Corporations Act 2001 for the financial year ending 30 June 2018. This declaration is made in accordance with a resolution of the directors. Greg Tweedly Director and Chairman Andrew Ronchi Director and CEO Melbourne Date: 19 September 2018 Melbourne Date: 19 September 2018 dorsaVi Annual Report 2018 59 dorsaVi Ltd and controlled entities  ABN 15 129 742 409  INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF dorsaVi Ltd  Report on the Audit of the Financial Report  Opinion   We have audited the financial report of dorsaVi Ltd “the Company”, which comprises the statement of financial  position  as  at  30  June  2018,  the  statement  of  comprehensive  income,  statement  of  changes  in  equity  and  statement of cash flows for the year then ended, and notes to the financial statements, including a summary of  significant accounting policies, and the directors’ declaration.  In our opinion, the accompanying financial report of dorsaVi Ltd, is in accordance with the Corporations Act  2001, including:   (a) giving  a  true  and  fair  view  of  the  Company’s  financial  position  as at  30  June 2018 and  of  its  financial performance for the year then ended; and (b) complying with Australian Accounting Standards and the Corporations Regulations 2001. Basis for Opinion   We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those  standards are further described in the Auditor’s Responsibilities for the Audit of a Financial Report section of  our report. We are independent of the Company in accordance with the auditor independence requirements  of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical  Standards Board’s APES 110 Code of Ethics for Professional Accountants “the Code” that are relevant to our  audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance  with the Code.   We confirm that the independence declaration required by the Corporations Act 2001, which has been given  to the directors of the Company would be in the same terms if given to the directors as at the time of this  auditor’s report.  We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our  opinion.   Material Uncertainty Related to Going Concern  We draw attention to Note 1(b) in the financial report, which indicates that the Group incurred a net loss of  $3,727,073 during the year ended 30 June 2018 and had total net cash outflows of $4,642,745.  As at 30 June  2018, the Group’s current cash reserves total $3,966,857.  As stated in Note 1(b), these events or conditions,  along with other matters as set forth in Note 1(b), indicate that a material uncertainty exists that may cast  significant doubt on the Group’s ability to continue as a going concern. Our opinion is not modified in respect  of this matter.  Key Audit Matters   Key audit matters are those matters that, in our professional judgement, were of most significance in our audit  of the financial report of the current period. These matters were addressed in the context of our audit of the  financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on  these matters.   An independent Victorian Partnership ABN 30 771 674 745 Level 13, 664 Collins Street, Docklands VIC 3008  Liability limited by a scheme approved under Professional Standards Legislation Pitcher Partners is an association of independent firms Melbourne  |  Sydney  |  Perth  |  Adelaide  |  Brisbane|  Newcastle  An independent member of Baker Tilly International 60dorsaVi Ltd and controlled entities  ABN 15 129 742 409  INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF dorsaVi Ltd  Key Audit Matter  Recognition of revenue‐ $4,394,271  Refer to Note 4 ‘Revenue and other income’  The Group’s three largest revenue streams are:   The sale of devices and consumables,  Rental of devices; and,  The provision of consulting services. service  stream  revenue  Consulting  (FY18:  $1,842,411,  FY17:  $1,911,091)  includes  contracts  that account for revenue based on the percentage  of completion method, calculated on management’s  estimation of work completed to balance date and  against set project milestones.  How our audit addressed the key audit matter   Our procedures included amongst others:   Obtaining  an  understanding  of  the  accounting processes and internal controls relating to the cycle; Evaluating  managements’  process  regarding  the recognition  of  revenue  for  consulting  services, which includes a review of the project management system utilised; Obtaining  an  understanding  of  the  milestone  and task completion tracking capability, and the internal project delivery function; Selecting a sample of contracts, and performing the following procedures:    The  accurate  recording  of  consulting  service  revenue  is  highly  dependent  on  management’s  internal  project  management  system,  in  order  to  track the completion of milestones and tasks.  Key  elements  of  the  internal  project  management  system includes:   Accurately  estimating  total  effort  to  complete project at initiation of the contract;  Management’s  estimation  of  work  completed  to date; and Estimate  of  the  cost  to  complete,  including identification of potential project over‐runs. We focused on this area as a key audit matter due to  the number and type of estimation events over the  course of the contract life, in determining revenue  recognition for consulting services.  o Obtaining  and  agreeing  the  original contract and associated terms; o Assessing  the  revenue  recognised  under the  percentage  of  completion  method, including  to  date,  effort remaining  and  an  assessment  of  any applicable  changes  to  scope  or  delivery issues; the  effort  o Agreeing  progress  payments  made  by customers  for  projects  with  billing milestones in order to assess the likelihood of  the  recovery  for  the  works  completed; and, o Evaluating  contract  performance  in  the period  since  balance  date  to  determine whether  there  have  been  any  material adverse  changes  and  potential  project over‐runs in the delivery of projects. An independent Victorian Partnership ABN 30 771 674 745 Level 13, 664 Collins Street, Docklands VIC 3008  Liability limited by a scheme approved under Professional Standards Legislation Pitcher Partners is an association of independent firms Melbourne  |  Sydney  |  Perth  |  Adelaide  |  Brisbane|  Newcastle  An independent member of Baker Tilly International 61dorsaVi Ltd and controlled entities  ABN 15 129 742 409  INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF dorsaVi Ltd  Key Audit Matter  Capitalisation and carrying value of  development costs ‐ $1,821,350  Refer to Note 12 ‘Intangible Assets’  The  research  and  development  of  new  and  existing  technology  is  part  of  the  project  Group’s  undertaken  represents  an  investment  made  by  the  business,  for  which  future  economic  benefits  are  expected  to  be  derived.    operations.  Each  The  capitalisation  of  any  development  costs  is  highly  subject  to  management  judgement and is also subject to various  recognition  criteria  as  per  AASB  138  Intangible assets.  Key  management  considerations  to  be  made include the following:   Stage  of  the  development  cycle  ‐ research vs development; Ability  to  accurately  record  and allocate costs incurred for individual projects,  including  employee  costs; and Technical and commercial viability of individual projects undertaken   We focused on capitalised development  costs  as  a  key  audit  matter  due  to  the  number  and  type  of  judgement  and  estimation  events  required  and  the  ongoing operating losses of the Group.   How our audit addressed the key audit matter   Our procedures included amongst others:    Obtaining  an  understanding  of  the  accounting  processes  and internal controls relating to the capitalisation of development costs; Selecting  from  a  sample  of transactions    from  the  capitalised development costs and performing the following:        Obtaining  and  reviewing  management  reconciliations  for the amounts capitalised; Testing  the  mathematical  accuracy  of  reconciliations prepared for costs that had been capitalised; Reviewing  the  employee  costs  allocated  to  the  different development  projects,  and  testing  a  sample  of  employee rates  and  captured  hours  for  the  internal  amounts capitalised and tracing to timesheets; Reviewing  the  external  contractor  costs  allocated  to  the different  development  projects,  and  sampling  and  testing contractor costs to supporting information to substantiate the expenditure; the Evaluating  management’s  process  capitalisation  of  development  costs,  and  reviewing development projects against the recognition criteria as per AASB 138 Intangible assets; Challenging  management  of  both  the  development  and operations  teams  to  assess  the  technical  and  commercial viability/  the development costs capitalised; and Evaluating  management’s  including: commercialisation  expectations  surrounding  calculations, impairment  of  o Assessing  the  Group’s  discounted  cash  flow including plans,  forecast  expenditure  and business  and  forecasts  completeness  of  commitments; o Reviewing and challenging the assumptions used in the cash flow forecasts; o Assessing  the  discount  rate  used  in  the    Group’s cash  flow  forecast,  and  performing  sensitivity analysis on forecast model; o Assessing the reliability of managements sales and revenue pipeline for FY19 budgeted result; and o Obtaining  post  year‐end  financial  information  to assess  the  financial  performance  of  the  Group against budget. An independent Victorian Partnership ABN 30 771 674 745 Level 13, 664 Collins Street, Docklands VIC 3008  Liability limited by a scheme approved under Professional Standards Legislation Pitcher Partners is an association of independent firms Melbourne  |  Sydney  |  Perth  |  Adelaide  |  Brisbane|  Newcastle  An independent member of Baker Tilly International 62dorsaVi Ltd and controlled entities  ABN 15 129 742 409  INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF dorsaVi Ltd  Other Information  The  directors  are  responsible  for  the  other  information.  The  other  information  comprises  the  information  included in the Company’s annual report for the year ended 30 June 2018, but does not include the financial  report and our auditor’s report thereon.   Our opinion on the financial report does not cover the other information and accordingly we do not express any  form of assurance conclusion thereon.   In connection with our audit of the financial report, our responsibility is to read the other information and, in  doing  so,  consider  whether  the  other  information  is  materially  inconsistent  with  the  financial  report  or  our  knowledge obtained in the audit or otherwise appears to be materially misstated.   If,  based  on  the  work  we  have  performed,  we  conclude  that  there  is  a  material  misstatement  of  this  other  information, we are required to report that fact. We have nothing to report in this regard.   Responsibilities of the Directors for the Financial Report  The directors of the Company are responsible for the preparation of the financial report that gives a true and  fair  view  in  accordance  with  Australian  Accounting  Standards  and  the  Corporations  Act  2001  and  for  such  internal control as the directors determine is necessary to enable the preparation of the financial report that  gives a true and fair view and is free from material misstatement, whether due to fraud or error.   In preparing the financial report, the directors are responsible for assessing the Company’s ability to continue  as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis  of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no  realistic alternative but to do so.   Auditor’s Responsibilities for the Audit of the Financial Report   Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from  material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion.  Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance  with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements  can  arise  from  fraud  or  error  and  are  considered  material  if,  individually  or  in  the  aggregate,  they  could  reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.   As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement  and maintain professional scepticism throughout the audit. We also:    Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors. An independent Victorian Partnership ABN 30 771 674 745 Level 13, 664 Collins Street, Docklands VIC 3008  Liability limited by a scheme approved under Professional Standards Legislation Pitcher Partners is an association of independent firms Melbourne  |  Sydney  |  Perth  |  Adelaide  |  Brisbane|  Newcastle  An independent member of Baker Tilly International 63dorsaVi Ltd and controlled entities  ABN 15 129 742 409  INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF dorsaVi Ltd   Conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material  uncertainty  exists,  we  are  required  to  draw  attention  in  our  auditor’s  report  to  the  related disclosures  in  the  financial  report  or,  if  such  disclosures  are  inadequate,  to  modify  our  opinion.  Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.  Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and  whether  the  financial  report  represents  the  underlying  transactions  and  events  in  a  manner  that achieves fair presentation. We communicate with the directors regarding, among other matters, the planned scope and timing of the audit  and significant audit findings, including any significant deficiencies in internal control that we identify during our  audit.   We  also  provide  the  directors  with  a  statement  that  we  have  complied  with  relevant  ethical  requirements  regarding  independence,  and  to  communicate  with  them  all  relationships  and  other  matters  that  may  reasonably be thought to bear on our independence, and where applicable, related safeguards.   From the matters communicated with the directors, we determine those matters that were of most significance  in the audit of the financial report of the current period and are therefore the key audit matters. We describe  these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or  when, in extremely rare circumstances, we determine that a matter should not be communicated in our report  because the adverse consequences of doing so would reasonably be expected to outweigh the public interest  benefits of such communication.   Report on the Remuneration Report  Opinion on the Remuneration Report  We have audited the Remuneration Report included in pages 17 to 26 of the directors’ report for the year ended  30 June 2018. In our opinion, the Remuneration Report of dorsaVi Ltd, for the year ended 30 June 2018 complies  with section 300A of the Corporations Act 2001.   Responsibilities   The directors of the Company are responsible for the preparation and presentation of the Remuneration Report  in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the  Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.   F V RUSSO       Partner       19 September 2018        PITCHER PARTNERS              Melbourne  An independent Victorian Partnership ABN 30 771 674 745 Level 13, 664 Collins Street, Docklands VIC 3008  Liability limited by a scheme approved under Professional Standards Legislation Pitcher Partners is an association of independent firms Melbourne  |  Sydney  |  Perth  |  Adelaide  |  Brisbane|  Newcastle  An independent member of Baker Tilly International 64dorsaVi Ltd and controlled entities ABN: 15 129 742 409 SHAREHOLDER INFORMATION Corporate Governance The Group’s Corporate Governance Statement can be obtained at http://dorsavi.com/investor-relations/ Overview The Group’s securities are listed for quotation in the form of Ordinary Shares on the Australian Securities Exchange (ASX) and trade under the symbol “DVL”. The shareholder information below was applicable as at 31 August 2018. The Group’s share capital was as follows: Type of Security Ordinary Shares Options Performance Rights Substantial Holders Names of Holders Number of Securities 167,918,222 829,166 2,005,416 Number of Holders 712 3 7 Number of Shares Held % of Total Shares Starfish Technology Fund II, LP, Starfish Ventures, Michael Panaccio and Christiana Panaccio and Micana Family Trust AR BSM Pty Ltd and Andrew Ronchi 72,767,755 8,406,546 43.34% 5.01% Unmarketable Parcels Based on the closing market price on 31 August 2018, there were 201 shareholders holding less than a marketable parcel (i.e. a parcel of securities of less than $500). Options and Performance Rights (not listed on ASX) There were 829,166 unquoted options on issue to purchase ordinary shares under the Group’s Incentive Stock Option Agreement. The Options have been issued in accordance with the terms and conditions of the dorsaVi Ltd 2013 Share Ownership Plan. There were 2,005,416 unquoted Performance Rights granted, but not vested into ordinary shares, under the Group’s Incentive Agreements. The Performance Rights have been granted in accordance with the terms and conditions of the dorsaVi Ltd 2013 Share Ownership Plan. Restricted Securities and Escrow Agreements There are no securities which are restricted or subject to escrow agreements. Voting Rights At a general meeting, each Shareholder present (in person or by proxy, attorney or representative) has one vote on a show of hands and one vote for each share held when voting is done via a poll. Proxy forms will be included in each notice of meeting sent to Shareholders. Holders of issued but unexercised options are not entitled to vote. Required Statements a) b) There is no current on-market buy-back of the Group’s securities. The Group’s securities are not quoted on any exchange other than the ASX. dorsaVi Annual Report 2018 65 Distribution Schedule Number of Shares 1 – 1,000 1,001 - 5,000 5,001 - 10,000 10,001 – 100,000 100,001 and above Total dorsaVi’s Top 20 Shareholders dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Number of Holders 31 166 98 250 167 712 Set out below is a schedule of the 20 largest holders of each class of securities quoted. Rank Name of Registered Holder STARFISH TECHNOLOGY FUND II LP AR BSM PTY LTD STARFISH TECHNOLOGY FUND II NOMINEES A PTY LTD STARFISH TECHNOLOGY FUND II NOMINEES B PTY LTD CITICORP NOMINEES PTY LIMITED DRNEWNHAM SUPER PTY LTD UBS NOMINEES PTY LTD MS GABRIELLE BANAY GARSIND PTY LTD J P MORGAN NOMINEES AUSTRALIA LIMITED ANDREW RONCHI 1 2 3 4 5 6 7 8 9 10 11 12 MORRMAC PTY LTD 13 14 15 16 17 MR DANIEL RONCHI 18 MRS ROSALIND LAWRENCE 19 MR BRIAN TULLY + MRS MARGARET TULLY 20 LEVENSON INVESTMENTS PTY LTD DR BSM PTY LTD DANIEL RONCHI LOUANDI SUPER FUND PTY LTD CATWILLY PTY LTD Total shares held by top 20 shareholders Total shares held by all other shareholders No. of Shares Held 60,597,345 7,021,814 5,203,782 5,203,781 4,759,619 3,973,637 3,326,746 3,233,482 1,984,357 1,853,485 1,384,732 1,294,231 1,258,147 1,233,353 1,224,668 1,205,385 1,137,085 1,089,923 1,072,094 1,060,000 % 0f Total Shares 36.09 4.18 3.10 3.10 2.83 2.37 1.98 1.93 1.18 1.10 0.82 0.77 0.75 0.73 0.73 0.72 0.68 0.65 0.64 0.63 109,117,666 64.98 58,800,556 35.02 dorsaVi Annual Report 2018 66 Corporate Directory Board of Directors and Company Secretary Mr Gregory Tweedly Mr Ashraf Attia Dr Michael Panaccio Dr Andrew Ronchi Chairman Non-Executive Director Non-Executive Director Chief Executive Officer and Executive Director Non-Executive Director Company Secretary Ms Caroline Elliott Mr Brendan Case dorsaVi Ltd and controlled entities ABN: 15 129 742 409 Chief Executive Officer Chief Financial Officer Executive Team Dr Andrew Ronchi Mr Damian Connellan Mr David Erikson Ms Meagan Blackburn Ms Zoe Whyatt Mr Matthew May Ms Megan Connell Registered Office in Australia C/- Pitcher Partners, Level 13, 664 Collins Street, Melbourne, VIC 3000 Tel. +61 3 8610 5000 Principal Administrative Office Level 1, 120 Jolimont Rd, Melbourne East, VIC 3002 Tel. 1800 367 7284 Auditor Pitcher Partners Level 13, 664 Collins Street, Melbourne, VIC 3000 Tel: +61 3 8610 5000 Investor Relations Ms Rebecca Wilson Buchan Consulting Tel: +61 3 9866 4722 Share Registry Computershare Investor Services Pty Limited GPO BOX 242, Melbourne, VIC 3001 Tel: + 61 3 9415 5000 Annual General Meeting Date and Place The Annual General Meeting will be held Wednesday, 21 November 2018 at 10:00 am at: Offices of Pitcher Partners, Level 13, 664 Collins Street, Melbourne, Victoria, 3000 dorsaVi Annual Report 2018 67 dorsaVi Ltd and controlled entities ABN: 15 129 742 409 dorsaVi Annual Report 2018 68 

Continue reading text version or see original annual report in PDF format above